IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES

Inventors: Arthur M. Krieg; Joel N. Kline, both of Iowa City, IA (US)

Assignees: University of Iowa Research Foundation, Iowa City, IA (US); Coley Pharmaceutical Group, Inc., Wellesley, MA (US); The United States of America as represented by the Department of Health and Human Services, Washington, DC (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Appl. No.: 08/960,774
Filed: Oct. 30, 1997

Related U.S. Application Data

Continuation-in-part of application No. 18/738,652, filed on Oct. 30, 1996.

References Cited

U.S. PATENT DOCUMENTS
3,906,092 9/1975 Hilleman et al. .................... 424/89
5,248,670 9/1993 Draper et al. ...................... 514/44
5,585,479 12/1996 Hoke et al. ..................... 514/23.1
5,603,153 9/1997 Hutchinson et al. ............... 514/44
5,723,335 3/1998 Hutchinson et al. ............... 435/375
5,786,189 7/1998 Locht et al. ..................... 435/172.3
5,849,719 12/1998 Carson et al. ................... 514/44

FOREIGN PATENT DOCUMENTS
96/02555 2/1996 (WO).
97/28259 8/1997 (WO).

OTHER PUBLICATIONS


(List continued on next page.)
Primary Examiner—James Martinell
Attorney, Agent, or Firm—Wolf, Greenfield & Sacks, P.C.

ABSTRACT
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.

49 Claims, 19 Drawing Sheets


Blaxter et al., Genes expressed in Brugia malayi infective third stage larvae, Molecular and Biochemical Parasitology, 77:77–93 (Apr. 1996).

Fox, R.I., Mechanism of action of hydroxychloroquine as an antirheumatic drug, Chemical Abstracts 120:15, Abstract No. 182630 (Apr. 29, 1994).


Krieg AM et al., A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation, the Journal of Immunology, vol. 143, 2484–2451.


Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. *Antisense Nucleic Acid Drug Dev* 6(2):133–9, Summer 1996.


* cited by examiner
FIG. 2

TIME AFTER INJECTION (Hr)

(1w/6d) 6

10000 8000 6000 4000 2000

0 2 4 6 8
FIG. 3
<table>
<thead>
<tr>
<th>Treatment:</th>
<th>O</th>
<th>EC DNA</th>
<th>CT DNA</th>
<th>LPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>min.</td>
<td>0</td>
<td>15</td>
<td>30</td>
<td>15</td>
</tr>
</tbody>
</table>

**FIG. 7**
FIG. 8B

Panel A

Panel B

Panel C

Panel D

Panel E
FIG. 9

CELL COUNT, 10^6

TIME

1 HOUR  3 HOURS  8 HOURS  24 HOURS

SALINE, SALINE
OLIGO, SALINE
EGG, SEA
OLIGO/EGG, SEA
FIG. II

Percentage of cells for different conditions:
- **SALINE**
- **EGG,SEA**
- **CpG OLIGO/EGG,SEA**
- **CONTROL OLIGO/EGG,SEA**

Legend:
- MACROPHAGE
- LYMPHOCYTE
- NEUTROPHIL
- EOSINOPHIL
IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES

This application is a continuation-in-part of U.S. Ser. No. 08/738,652, filed Oct. 30, 1996.

The work resulting in this invention was supported in part by National Institute of Health Grant No. R29-AR2556-01. The U.S. Government may be entitled to certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least one unmethylated CpG dinucleotide which are immunostimulatory.

BACKGROUND OF THE INVENTION


Lymphocyte ODN uptake has been shown to be regulated by cell activation. Spleen cells stimulated with the B cell mitogen LPS had dramatically enhanced ODN uptake in the B cell population, while spleen cells treated with the T cell mitogen Con A showed enhanced ODN uptake by T but not B cells (Krieg, A. M., F. Gmelig-Meyling, M. F. Gourley, W. J. Kisch, L. A. Chrisey, and A. D. Steinberg. 1991. "Uptake of oligodeoxynucleotides by lymphoid cells is heterogeneous and inducible." Antisense Research and Development 1:161).


Several observations suggest that certain DNA structures may also have the potential to activate lymphocytes. For example, Bell et al. reported that nucleosomal protein-DNA complexes (but not naked DNA) in spleen cell supernatants caused B cell proliferation and immunoglobulin secretion (Bell, D.A., M. Morrison, and P. Van den Bergaart. 1990).
“Immunogenic DNA-related factors”. J. Clin. Invest. 85:1487. In other cases, naked DNA has been reported to have immune effects. For example, Messina et al. have recently reported that 260 to 800 bp fragments of poly(dG),(dC) and poly(dG,dC) were mitogenic for B cells (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1993. “The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens”. Cell. Immunol. 147:148). Tokunaga, et al. have reported that dG.dC induces γ-IFN and NK activity (Tokunaga, S. Yamamoto, and K. Namura. 1988. “A synthetic single-stranded DNA, poly(dG,dC), induces interferon-γ/b and γ-gamma interferon activity, and suppresses tumor growth”. Jpn. J. Cancer Res. 79:682). Aside from such artificial homopolymer sequences, Pisetsky et al. reported that pure mammalian DNA has no detectable immune effects, but that DNA from certain bacteria induces B cell activation and immunoglobulin secretion (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1991. “Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA”. J. Immunol. 147:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation. Investigations of mycobacterial DNA sequences have demonstrated that ODN which contain certain palindromic sequences can activate NK cells (Yamamoto, S., T. Yamamoto, T. Kataoka, E. Karamoto, O. Yano, and T. Tokunaga. 1992. “Unique palindromic sequences in synthetic oligonucleotides are required to induce INF-γ and augment IFN-mediated natural killer activity”. J. Immunol. 148:4072; Karamoto, E., O. Yano, Y. Kimura, M. Baba, T. Makino, S. Yamamoto, T. Yamamoto, T. Kataoka, and T. Tokunaga. 1992. “Oligonucleotide sequences required for natural killer cell activation”. Jpn. J. Cancer Res. 83:1128). Several phosphorothioate modified ODN have been reported to induce in vitro or in vivo B cell stimulation (Tanaka, T., C. C. Chu, and W. E. Paul. 1992. “An antisense oligonucleotide complementary to a sequence in Ig2 increases g2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion”. J. Exp. Med. 175:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation. Investigations of mycobacterial DNA sequences have demonstrated that ODN which contain certain palindromic sequences can activate NK cells. Several phosphorothioate modified ODN have been reported to induce in vitro or in vivo B cell stimulation (Tanaka, T., C. C. Chu, and W. E. Paul. 1992. “An antisense oligonucleotide complementary to a sequence in Ig2 increases g2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion”. J. Exp. Med. 175:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation. Investigations of mycobacterial DNA sequences have demonstrated that ODN which contain certain palindromic sequences can activate NK cells.


Aside from their critical role in regulating cellular transcription, it has recently been shown that CREB/ATF proteins are subverted by some infectious viruses and retroviruses, which require them for viral replication. For example, the cytomegalovirus immediate early promoter, one of the strongest known mammalian promoters, contains eleven copies of the CRE which are essential for promoter function (Chang, Y.-N., S. Crawford, J. Stall, D. R. Rawlinson, K.-T. Jeang, and G. S. Hayward: “The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements”. J. Virol. 64:264, 1990). At least some of the transcriptional activating effects of the adenovirus EIA protein, which induces many promoters, are due to its binding to the DNA binding domain of the CREB/ATF protein, ATF-2, which mediates EIA inducible transcription activation (Lin, E., and M. R. Green: “Promoters targeting by adenovirus EIA through interaction with different cellular DNA-binding domains”. Nature 368:520, 1994). It has also been shown that EIA binds to the CRE-binding protein, CBP (Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner: “EIA-associated p300 and CREB-associated CBP belong to a conserved family of coactivators”. Cell 77:799, 1994). Human T lymphotropic virus-I (HTLV-I), the retrovirus which causes human T-cell leukemia and tropical spastic paraparesis, also requires CREB/ATF proteins for replication. In this case, the retrovirus produces a protein, Tax, which binds to CREB/ATF proteins and redirects them from their normal cellular binding sites to different DNA sequences (flanked by G- and C-rich sequences) present within the HTLV transcriptional enhancer (Paca-Uccarerluk, S., J.-L. Zhao, N. Adya, J. V. Cross, B. R. Cullen, I. M. Boros, and C.-Z. Giam: “In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, Tax”. Mol. Cell Biol. 14:456, 1994; Adya, N., J.-L. Zhao, W. Huang, I. Boros, and C.-Z. Giam: “Expansion of CREB’s DNA binding domain by targeted mutagenesis by Ala-Ala-Arg at positions 282–284 near the conserved DNA-binding domain of CREB”. Proc. Natl. Acad. Sci. USA 91:5642, 1994).
Furthermore, by redirecting a subject’s immune response from Th2 to Th1, the claimed nucleic acid sequences can be used to treat or prevent an asthmatic disorder. In addition, the claimed nucleic acid molecules can be administered to a subject in conjunction with a particular allergen as a type of desensitization therapy to treat or prevent the occurrence of an allergic reaction associated with an asthmatic disorder. Further, the ability of the nucleic acid sequences of the invention described herein to induce leukemic cells to enter the cell cycle supports their use in treating leukemia by increasing the sensitivity of chronic leukemia cells followed by conventional ablative chemotherapy, or by combining the nucleic acid sequences with other immunotherapies.

Other features and advantages of the invention will become more apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A–C are graphs plotting dose-dependent IL-6 production in response to various DNA sequences in T cell depleted spleen cell cultures.

FIG. 1 A. E. coli DNA (■) and calf thymus DNA (□) sequences and LPS (at 10x the concentration of E. coli and calf thymus DNA) (△).

FIG. 1 B. Control phosphodiester oligodeoxynucleotide (ODN) 5′ATTGGAAGTGCCAGGTTCCTC (SEQ ID No: 1) (■) and two phosphodiester CpG ODN 5′ATCGAC-CTAAGTCCTGATG (SEQ ID No: 2) (●) and 5′TCCAT-AACGTTTCGATGCT (SEQ ID No: 3) (○).

FIG. 1 C. Control phosphorothioate ODN 5′GCTAGA-GGTAGCTT (SEQ ID No: 4) (■) and two phosphorothioate CpG ODN 5′GAGAACGTCCGTCCTGAT (SEQ ID No: 5) (●) and 5′GCATAGACGTGCTT (SEQ ID No: 6) (○). Data present the mean±standard deviation of triplicates.

FIG. 2 is a graph plotting IL-6 production induced by CpG DNA in vivo as determined 1–8 hrs after injection. Data represent the mean of duplicate analyses of sera from two mice. BALB/c mice (two mice/group) were injected iv with 100 µl of PBS (○) or 200 µg of CpG phosphorothioate ODN 5′TCCATAGACGTCCGATGCT (SEQ ID No: 7) (■) or non-CpG phosphorothioate ODN 5′TCCATAGACGTCCGATGCT (SEQ ID No: 8) (○).

FIG. 3 is an autoradiograph showing IL-6 mRNA expression as determined by reverse transcription polymerase chain reaction in liver, spleen, and thymus at various time periods during iv in vivo stimulation of BALB/c mice (two mice/group) injected iv with 100 µl of PBS, 200 µg of CpG phosphorothioate ODN 5′TCCATAGACGTCCGATGCT (SEQ ID No: 7) or non-CpG phosphorothioate ODN 5′TCCATAGACGTCCGATGCT (SEQ ID No: 8) (►).

FIG. 4A is a graph plotting dose-dependent inhibition of CpG-induced IgM production by anti-IL-6. Splenic B-cells from DBA/2 mice were stimulated with CpG ODN 5′TCCAAAGCTTCCAGT (SEQ ID No: 9) in the presence of the indicated concentrations of neutralizing anti-IL-6 (●) or isotype control Ab (■) and IgM levels in culture supernatants determined by ELISA. In the absence of CpG ODN, the anti-IL-6 Ab had no effect on IgM secretion (■).

FIG. 4B is a graph plotting the stimulation index of CpG-induced splenic B cells cultured with anti-IL-6 and CpG S-ODN 5′TCCATAGACGTCCGATGCT (SEQ ID No: 7) (●) or anti-IL-6 antibody only (■). Data present the mean±standard deviation of triplicates.

FIG. 5 is a bar graph plotting chloramphenicol acetyltransferase (CAT) activity in WEHI-231 cells transfected with a promoter-less CAT construct (pCAT), positive control plasmid (RSV), or IL-6 promoter-CAT construct alone or cultured with CpG 5′TCCATAGACGTCCGATGCT (SEQ ID No: 7) or non-CpG 5′TCCATAGACGTCCGATGCT (SEQ ID No: 8) phosphorothioate ODN at the indicated concentrations. Data present the mean of triplicates.

FIG. 6 is a schematic overview of the immune effects of the immunostimulatory unmethylated CpG containing nucleic acids, which can directly activate both B cells and mononuclear cells (including macrophages and dendritic cells) as shown. The immunostimulatory oligonucleotides do not directly activate purified NK cells, but render them competent to respond to IL-12 with a marked increase in their IFN-γ production. By inducing IL-12 production and the subsequent increased IFN-γ secretion by NK cells, the immunostimulatory nucleic acids promote a Th1 type immune response. No direct activation of proliferation of cytokine secretion by highly purified T cells has been found. However, the induction of Th1 cytokine secretion by the immunostimulatory oligonucleotides promotes the development of a cytotoxic lymphocyte response.

FIG. 7 is an autoradiograph showing NF-KB mRNA induction in monocytes treated with E. coli (EC) DNA (containing unmethylated CpG motifs), control (CT) DNA (containing no unmethylated CpG motifs) and lipopolysaccharide (LPS) at various measured times, 15 and 30 minutes after contact.

FIG. 8A shows the results from a flow cytometry study using mouse B cells with the dihydrodorhamidine 123 dye to determine levels of reactive oxygen species. The dye only sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%. This level of reactive oxygen species was greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B). The cells treated with the CpG oligo (TCCATGACGTCCGATGCTT SEQ ID No: 10) also showed an increase in the level of reactive oxygen species such that more than 90% of the cells became positive (Panel D). However, cells treated with an oligonucleotide with the identical sequence except that the CpGs were switched (TCCATGACGTCCGATGCTT SEQ ID NO. 11) did not show this significant increase in the level of reactive oxygen species (Panel E).

FIG. 8B shows the results from a flow cytometry study using mouse B cells in the presence of chloroquine with the dihydrodorhamidine 123 dye to determine levels of reactive oxygen species. Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E).

FIG. 9 is a graph plotting lung lavage cell count over time. The graph shows that when the mice are initially injected with Schistosoma mansoni eggs “egg”, which induces a Th2 immune response, and subsequently inhale Schistosoma mansoni egg antigen “SEA” (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given CpG oligo (SEQ ID NO. 10) along with egg, the inflammatory cells in the lung are not increased by subsequent inhalation of SEA (open triangles).

FIG. 10 is a graph plotting lung lavage eosinophil count over time. Again, the graph shows that the mice are initially injected with egg and subsequently inhale SEA (open circle), many eosinophils are present in the lungs. However, when the mice are initially given CpG oligo (SEQ
ID NO. 10) along with egg, the inflammatory cells in the lung are not increased by subsequent inhalation of the SEA (open triangles).

FIG. 11 is a bar graph plotting the effect on the percentage of macrophage, lymphocyte, neutrophil and eosinophil cells induced by exposure to saline alone; egg, then SEA; egg and SEQ ID No. 11, then SEA; and egg and control olio (SEQ ID No. 11), then SEA. When the mice are treated with the control olio at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA. Thus, when mice inhale the eggs on days 14 or 21, they develop an acute inflammatory response in the lungs. However, giving a CpG olio along with the eggs at the time of initial antigen exposure on days 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.

FIG. 12 is a bar graph plotting eosinophil count in response to injection of various amounts of the protective olio SEQ ID No. 10.

FIG. 13 is a graph plotting interleukin 4 (IL-4) production (pg/ml) in mice over time in response to injection of egg, then SEA (open diamond); egg and SEQ ID No. 10, then SEA (open circle); or saline, then saline (open square). The graph shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.

FIG. 14 is a bar graph plotting interleukin 12 (IL-12) production (pg/ml) in mice over time in response to injection of saline; egg, then SEA; or SEQ ID No. 10 and egg, then SEA. The graph shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of IL-12, indicating a Th1 type of immune response.

FIG. 15 is a bar graph plotting interferon gamma (IFN-γ) production (pg/ml) in mice over time in response to injection of saline; egg, then saline; or SEQ ID No. 10 and egg, then SEA. The graph shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN-γ, indicating a Th1 type of immune response.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein, the following terms and phrases shall have the meanings set forth below:

An “allergen” refers to a substance that can induce an allergic or asthmatic response in a susceptible subject. The list of allergens is enormous and can include pollens, insect venoms, animal dander dust, fungal spores and drugs (e.g. penicillin). Examples of natural, animal and plant allergens include proteins specific to the following genera: Canine (Canis familiaris); Dermatophagoides (e.g. Dermatophago- goides farinae); Felis (Felis domesticus); Ambrosia (Ambrosia artemisiifolia; Lolium (e.g. Lolium perenne or Lolium multiflorum); Cryptomeria (Cryptomeria japonica); Alternaria (Alternaria alternata); Alder; Alnus (Alnus glutinosa); Betula (Betula verrucosa); Quercus (Quercus alba); Olea (Olea europea); Artemisia (Artemisia vulgaris); Plantago (e.g. Plantago lanceolata); Parietaria (e.g. Pari- etaria officinalis or Parietaria judaica); Blattella (e.g. Blat- tella germanica); Apsis (e.g. Apsis multiflorum); Cupressus (e.g. Cupressus sempervirens; Cupressus arizonica and Cupressus macrocarpa); Juniperus (e.g. Juniperus sabinaoides, Juniperus virginiana, Juniperus communis and Juniperus ashei); Thuya (e.g. Thuja orientalis); Chamae- cyparis (e.g. Chamaecyparis obtusa); Periplaneta (e.g. Periplaneta americana); Agropyron (e.g. Agropyron repens); Secale (e.g. Secale cereale); Triticum (e.g. Triticum aestivum); Dactylis (e.g. Dactylis glomerata); Festuca (e.g. Festuca elatior); Poa (e.g. Poa pratensis or Poa compressa); Avena (e.g. Avena sativa); Holcus (e.g. Holcus lanatus); Anthoxanthum (e.g. Anthoxanthum odoratum); Arrhenatherum (e.g. Arrhenatherum elatius); Agrostis (e.g. Agros- tis alba); Phleum (e.g. Phleum pratense); Phalaris (e.g. Phalaris arundinacea); Paspalum (e.g. Paspalum notatum); Sorghum (e.g. Sorghum halepense); and Bromus (e.g. Bromus inermis).

An “allergy” refers to acquired hypersensitivity to a substance (allergen). Allergic conditions include eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, urticaria (hives) and food allergies, and other atopic conditions.

“Asthma”—refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.

An “immune system deficiency” shall mean a disease or disorder in which the subject’s immune system is not functioning in normal capacity or in which it would be useful to boost a subject’s immune response for example to eliminate a tumor or cancer (e.g. tumors of the brain, lung (e.g. small cell and non-small cell), ovary, breast, prostate, colon, as well as other carcinomas and sarcomas) or an infection in a subject.

Examples of infectious virus include: Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, HIV-2, HTLV-IV, HIV-LAV, or HIV-III), and other isolates, such as HIV-IP, Piconnaiviridae (e.g., polio viruses, hepatitis A virus, enteroviruses, human coxsackie viruses, rhinoviruses, echoviruses); Caliciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses); Coronaviridae (e.g., coronavirus); Rhabdoviridae (e.g., vesicular stomatitis viruses, rabies viruses); Filiviridae (e.g., ebola viruses); Paramyxoviridae (e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza viruses); Bungaviridae (e.g., Hantaan viruses, bungo viruses, phlebo viruses and Nairo viruses); Arena viruses (hemorrhagic fever viruses); Paroviridae (e.g., reoviruses, orbiviruses and rotaviruses); Birnaviridae; Hepadnaviridae (Hepatitis B virus); Paroviridae (paroviruses); Pappovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes viruses); Poxviridae (vaccinia viruses, variola virus, pox viruses); and Iridoviridae (e.g., African swine fever virus); and unclassified viruses (e.g., the eutrophic agents of Spongilla encephalopathies, the agent of delta hepatitides (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1 internally transmitted, class 2 parenterally transmitted (i.e., Hepatitis C), Norwalk and related viruses, and astroviruses).

Examples of infectious bacteria include: Helicobacter pylori, Borella burgdorferi, Legionella pneumophilia, Mycobacteria spp (e.g. M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A
Streptococcus), Streptococcus agalactiae (Group B Streptococcus), Streptococcus viridans group, Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic sps.), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus antracis, Corynebacterium diphtheriae, corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, and Actinomyces israelii.

Examples of infectious fungi include: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans. Other infectious organisms (i.e., prokaryots) include: Plasmodium falciparum and Toxoplasma gondii.

An "immunostimulatory nucleic acid molecule" refers to a nucleic acid molecule, which contains an unmethylated cytosine, guanine dinucleotide sequence (i.e., "CpG DNA" or DNA containing a cytosine followed by a guanine and linked by a phosphate bond) and stimulates (e.g. has a mitogenic effect on, or induces or increases cytokine expression by) a vertebrate lymphocyte. An immunostimulatory nucleic acid molecule can be double-stranded or single-stranded. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity.

In one preferred embodiment the invention provides an isolated immunostimulatory nucleic acid sequence containing a CpG motif represented by the formula:

\[ 5'N_XCNGX_N3' \]

wherein at least one nucleotide separates consecutive CpGs; \( X_1 \) is adenine, guanine, or thymine; \( X_2 \) is cytosine or thymine; \( N \) is any nucleotide and \( N_4+N_5 \) is from about 0–26 bases with the proviso that \( N_2 \) and \( N_4 \) do not contain a CGG quadmer or more than one CGG or CGG trimer; and the nucleic acid sequence is from about 8–30 bases in length.

In another embodiment the invention provides an isolated immunostimulatory nucleic acid sequence contains a CpG motif represented by the formula:

\[ 5'N_XXCGNX_N3' \]

wherein at least one nucleotide separates consecutive CpGs; \( X_1 \) and \( X_2 \) is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; \( X_1 \) is selected from the group consisting of TpT or CpT; \( N \) is any nucleotide and \( N_4+N_5 \) is from about 0–26 bases with the proviso that \( N_1 \) and \( N_2 \) do not contain a CGG quadmer or more than one CGG or CGG trimer; and the nucleic acid sequence is from about 8–30 bases in length.

Preferably the immunostimulatory nucleic acid sequences of the invention include \( X_1 \) and \( X_2 \) selected from the group consisting of GpT, GpG, GpA and ApT and ApA and \( X_1 \) selected from the group consisting of TpT or CpT and GpT (see, for example, Table 3). For facilitating uptake into cells, CpG containing immunostimulatory nucleic acid molecules are preferably in the range of 8 to 30 bases in length. However, nucleic acids of any size (even many kb long) are immunostimulatory if sufficient immunostimulatory motifs are present, since such larger nucleic acids are degraded into oligonucleotides inside of cells. Preferably synthetic oligonucleotides do not include a a CGG quadmer or more than one CGG or CGG trimer at or near the 5' and/or 3' terminals and/or the consensus mitogenic CpG motif is not a palindrome. Prolonged immunostimulation can be obtained using stabilized oligonucleotides, where the oligonucleosome incorporates a phosphate backbone modification. For example, the modification is a phosphorothioate or phosphorodithioate modification. More particularly, the phosphate backbone modification occurs at the 5' end of the nucleic acid for example, at the first two nucleotides of the 5' end of the nucleic acid. Further, the phosphate backbone modification may occur at the 3' end of the nucleic acid for example, at the last five nucleotides of the 3' end of the nucleic acid.

Preferably the immunostimulatory CpG DNA is in the range of between 8 to 30 bases in size when it is an oligonucleotide. Alternatively, CpG dinucleotides can be produced on a large scale in plasmids, which after being administered to a subject are degraded into oligonucleotides. Preferred immunostimulatory nucleic acid molecules (e.g. for use in increasing the effectiveness of a vaccine or to treat an immune system deficiency by stimulating an antibody (i.e., humoral) response in a subject) have a relatively high stimulation index with regard to B cell, monocyte and/or natural killer cell responses (e.g. cytokine, proliferative, lytic or other responses).

The nucleic acid sequences of the invention stimulate cytokine production in a subject for example. Cytokines include but are not limited to IL-6, IL-12, IFN-γ, TNF-α and GM-CSF. Exemplary sequences include: TCCAGTCGGTCGTCA (SEQ ID NO: 37), TCCAGTCGGTCGTCA (SEQ ID NO: 38), and TCCAGTCGGTCGTCA (SEQ ID NO: 46).

The nucleic acid sequences of the invention are also useful for stimulating natural killer cell (NK) lytic activity in a subject such as a human. Specific, but non-limiting examples of such sequences include: TCCAGTCGGTCGTCA (SEQ ID NO: 47), TCCAGTCGGTCGTCA (SEQ ID NO: 46), TCCAGTCGGTCGTCA (SEQ ID NO: 49), GGGTCAGTCGGTCGTCA (SEQ ID NO: 50), TCCAGTCGGTCGTCA (SEQ ID NO: 48), TCCAGTCGGTCGTCA (SEQ ID NO: 50) and TCCAGTCGGTCGTCA (SEQ ID NO: 51).

The nucleic acid sequences of the invention are also useful for stimulating B cell proliferation in a subject such as a human. Specific, but non-limiting examples of such sequences include: TCCAGTCGGTCGTCA (SEQ ID NO: 52), TCCAGTCGGTCGTCA (SEQ ID NO: 53), TCCAGTCGGTCGTCA (SEQ ID NO: 54), TCCAGTCGGTCGTCA (SEQ ID NO: 54), TCCAGTCGGTCGTCA (SEQ ID NO: 46), TCCAGTCGGTCGTCA (SEQ ID NO: 49) and TCCAGTCGGTCGTCA (SEQ ID NO: 50).

In another aspect, the nucleic acid sequences of the invention are useful as an adjuvant for use during antibody production in a mammal. Specific, but non-limiting examples of such sequences include: TCCAGTCGGTCGTCA (SEQ ID NO: 10), TCCAGTCGGTCGTCA (T/C)T. Furthermore, the claimed nucleic acid sequences can be administered to treat or prevent the symptoms of an asthmatic disorder by redirecting a subject's immune response from Th2 to Th1. An exemplary sequence includes TCCAGTCGGTCGTCA (SEQ ID NO: 10).

The stimulation index of a particular immunostimulatory CpG DNA can be tested in various immune cell assays. Preferably, the stimulation index of the immunostimulatory CpG DNA with regard to B-cell proliferation is at least about
5, preferably at least about 10, more preferably at least about 15 and most preferably at least about 20 as determined by incorporation of $^3$H uridine in a murine B cell culture, which has been contacted with a 20 μM of ODN for 20 h at 37°C and has been pulsed with 1 μCi of $^3$H uridine; and harvested and counted 4h later as described in detail in Example 1. For use in vivo, for example to treat an immune system deficiency by stimulating a cell-mediated (local) immune response in a subject, it is important that the immunostimulatory CpG DNA be capable of effectively inducing cytokine secretion by mononuclear cells and/or Natural Killer (NK) cell activity.

Preferred immunostimulatory CpG nucleic acids should effect at least about 500 pg/ml of TNF-α, 15 pg/ml IFN-γ, 70 pg/ml of GM-CSF 275 pg/ml of IL-6, 200 pg/ml of IL-12, depending on the therapeutic indication, as determined by the assays described in Example 12. Other preferred immunostimulatory CpG DNAs should effect at least about 10%, more preferably at least about 15% and most preferably at least about 20% YAC-1 cell specific lysis or at least about 30%, more preferably at least about 35% and most preferably at least about 40% 2C11 cell specific lysis as determined by the assays described in detail in Example 4.

A “nucleic acid” or “DNA” means multiple nucleotides (i.e., molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)). As used herein, the term refers to ribonucleotides as well as oligodeoxyribonucleotides. The term shall also include polynucleotides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g. genomic or cDNA), but are preferably synthetic (e.g. produced by oligonucleotide synthesis).

A “nucleic acid delivery complex” shall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell (e.g. B-cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with: a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor). Preferred complexes must be sufficiently stable in vivo to prevent significant uncoupling prior to internalization by the target cell. However, the complex should be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.

“Palindromic sequence” shall mean an inverted repeat (i.e., a sequence such as ABCDEEDCBA’ in which A and A’ are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double stranded structures.

A “stabilized nucleic acid molecule” shall mean a nucleic acid molecule that is relatively resistant to in vivo degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Unmethylated CpG containing nucleic acid molecules that are tens to hundreds of kbs long are relatively resistant to in vivo degradation. For shorter immunostimulatory nucleic acid molecules, secondary structures can stabilize and increase their effect. For example, if the 3' end of a nucleic acid molecule has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the nucleic acid molecule becomes stabilized and therefore exhibits more activity.

Preferred stabilized nucleic acid molecules of the instant invention have a modified backbone. For use in immune stimulation, especially preferred stabilized nucleic acid molecules are phosphorothioate (i.e., at least one of the phosphate oxygens of the nucleic acid molecule is replaced by sulfur) or phosphorothioate modified nucleic acid molecules. More particularly, the phosphate backbone modification occurs at the 5' end of the nucleic acid for example, at the first two nucleotides of the 5' end of the nucleic acid. Further, the phosphate backbone modification may occur at the 3' end of the nucleic acid for example, at the last five nucleotides of the 3' end of the nucleic acid. In addition to stabilizing nucleic acid molecules, as reported further herein, phosphorothioate-modified nucleic acid molecules (including phosphorothioate-modified) can increase the extent of immune stimulation of the nucleic acid molecule, which contains an unmethylated CpG dinucleotide as shown herein. International Patent Application Publication Number: WO 95/26204 entitled “Immune Stimulation By Phosphorothioate Oligonucleotide Analogs” also reports on the non-sequence specific immunostimulatory effect of phosphorothioate modified oligonucleotides. As reported herein, unmethylated CpG containing nucleic acid molecules having a phosphorothioate backbone have been found to preferentially activate B-cell activity, while unmethylated CpG containing nucleic acid molecules having a phosphodiester backbone have been found to preferentially activate monocyte (macrophages, dendritic cells and monocytes) and NK cells. Phosphorothioate CpG oligonucleotides with preferred human motifs, are also strong activators of monocyteic and NK cells.

Other stabilized nucleic acid molecules include: nonionic DNA analogs, such as alkyl- and aryl-phosphonates (in which the charged phosphate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphodiester, in which the charged oxygen moiety is alkylated. Nucleic acid molecules which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

A “subject” shall mean a human or vertebrate animal including a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat, and mouse.

As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Preferred vectors are those capable of autonomous replication and expression of nucleic acids to which they are linked (e.g., an episome). Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors.” In general, expression vectors of utility in recombinant DNA techniques are often in the form of “plasmids” which refer generally to circular double stranded DNA loops which, in their vector form, are not bound to the chromosome. In the present specification, “plasmid” and “vector” are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

Certain Unmethylated CpG Containing Nucleic Acids Have B Cell Stimulatory Activity As Shown in vitro and in vivo

In the course of investigating the lymphocyte stimulatory effects of two antisense oligonucleotides specific for endog-
enous retroviral sequences, using protocols described in the attached Examples 1 and 2, it was surprisingly found that two out of twenty-four “controls” (including various scrambled, sense, and mismatch controls for a panel of “antisense” ODN) also mediated B cell activation and IgM secretion, while the other “controls” had no effect.

Two observations suggested that the mechanism of this B cell activation by the “control” ODN may not involve antisense effects 1) comparison of vertebrate DNA sequences listed in GenBank showed no greater homology than that seen with non-stimulatory ODN and 2) the two controls showed no hybridization to Northern blots with 10 μg of spleen poly A+ RNA. Resynthesis of these ODN on a different synthesizer or extensive purification by polyacrylamide gel electrophoresis or high pressure liquid chromatography gave identical stimulation, eliminating the possibility of an impurity. Similar stimulation was seen using B cells from C3H/HeJ mice, eliminating the possibility that lipopolysaccharide (LPS) contamination could account for the results.

The fact that two “control” ODN caused B cell activation similar to that of the two “antisense” ODN raised the possibility that all four ODN were stimulating B cells through some non-antisense mechanism involving a sequence motif that was absent in all of the other nonstimulatory control ODN. In comparing these sequences, it was discovered that all of the four stimulatory ODN contained CpG dinucleotides that were in a different sequence context from the nonstimulatory control.

To determine whether the CpG motif present in the stimulatory ODN was responsible for the observed stimulation, over 300 ODN ranging in length from 5 to 42 bases that contained methylated, unmethylated, or no CpG dinucleotides in various sequence contexts were synthesized. These ODNs, including the two original “controls” (ODN 1 and 2) and two originally synthesized as “antisense” (ODN 3D and 3M; Krieg, A. M. J. Immunol. 143:2448 (1989)), were then examined for in vitro effects on spleen cells (representative sequences are listed in Table 1). Several ODN that contained CpG dinucleotides induced B cell activation and IgM secretion; the magnitude of this stimulation typically could be increased by adding more CpG dinucleotides (Table 1; compare ODN 2 to 2a or 3D to 3Da and 3Db). Stimulation did not appear to result from an antisense mechanism or impurity. ODN caused no detectable proliferation of γδ or other T cell populations.

Mitogenic ODN sequences uniformly became nonstimulatory if the CpG dinucleotide was mutated (Table 1; compare ODN 1 to 1a; 3D to 3Dc; 3M to 3Ma; and 4 to 4a) or if the cytosine of the CpG dinucleotide was replaced by 5-methylcytosine (Table 1; ODN 1b, 2b, 3Db, and 3Mb).

Partial methylation of CpG motifs caused a partial loss of stimulatory effect (compare 2a to 2c; Table 1). In contrast, methylation of other cytosines did not reduce ODN activity (ODN 1c, 2d, 3De and 3Mc). These data confirmed that a CpG motif is the essential element present in ODN that activate B cells.

In the course of these studies, it became clear that the bases flanking the CpG dinucleotide played an important role in determining the murine B cell activation induced by an ODN. The optimal stimulatory motif was determined to consist of a CpG flanked by two 5 purines (preferably a GaD dinucleotide) and two 3 pyrimidines (preferably a TpT or TpC dinucleotide). Mutations of ODN to bring the CpG motif closer to this ideal improved stimulation (e.g. Table 1, compare ODN 2 to 2e; 3M to 3Md) while mutations that disturbed the motif reduced stimulation (e.g. Table 1, compare ODN 3D to 3De; 4 to 4b, 4c and 4d). On the other hand, mutations outside the CpG motif did not reduce stimulation (e.g. Table 1, compare ODN 1 to 1d; 3D to 3Dg; 3M to 3Mc). For activation of human cells, the best flanking bases are slightly different (See Table 5).

Of those tested, ODNs shorter than 8 bases were non-stimulatory (e.g. Table 1, ODN 4c). Among the forty-eight 8 base ODN tested, a highly stimulatory sequence was identified as TCAAGCTT (ODN 4) which contains the self complementary “palindrome” AACGTT. In further optimizing this motif, it was found that ODN containing Gs at both ends showed increased stimulation, particularly if the ODN were rendered nuclease resistant by phosphorothioate modification of the terminal internucleotide linkages. ODN 1585 (5’GCGGTCACAAGCTTCAGGGG3’ (SEQ ID NO: 12)), in which the first two and last five internucleotide linkages are phosphorothioate modified caused an average 25.4 fold increase in mouse spleen cell proliferation compared to an average 3.2 fold increase in proliferation induced by ODN 1638, which has the same sequence as ODN 1585 except that the 10 Gs at the two ends, are replaced by 10 As. The effect of the G-rich ends is cis; addition of an ODN with poly G ends, but no CpG motif to cells along with 1638 gave no increased proliferation. For nucleic acid molecules longer than 8 base pairs, non-palindromic motifs containing an unmethylated CpG were found to be more immunostimulatory.

Other octamer ODN containing a 6 base palindrome with a TpC dinucleotide at the 5’ end were also active (e.g. Table 1, ODN 4b, 4c). Other dinucleotides at the 5’ end gave reduced stimulation (e.g., ODN 4f; all sixteen possible dinucleotides were tested). The presence of a 3’ dinucleotide was insufficient to compensate for the lack of a 5’ dinucleotide (e.g., Table 1, ODN 4g). Disruption of the palindrome eliminated stimulation in octamer ODN (e.g., Table 1, ODN 4h), but palindromes were not required in longer ODN.

<table>
<thead>
<tr>
<th>ODN</th>
<th>Sequence (5’ to 3’)</th>
<th>3′ Uridine</th>
<th>IgM Production</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(SEQ ID NO:91)</td>
<td>GCTAGACGATTACGTT</td>
<td>6.1 ± 0.8</td>
</tr>
<tr>
<td>1a</td>
<td>(SEQ. ID NO:14)</td>
<td>3TC............</td>
<td>1.2 ± 0.2</td>
</tr>
<tr>
<td>1b</td>
<td>(SEQ ID NO:13)</td>
<td>3Z............</td>
<td>1.2 ± 0.1</td>
</tr>
<tr>
<td>1c</td>
<td>(SEQ ID NO:14)</td>
<td>3Z............</td>
<td>10.3 ± 4.4</td>
</tr>
</tbody>
</table>

**TABLE 1**

Oligonucleotide Stimulation of Mouse B Cells
<table>
<thead>
<tr>
<th>ODN</th>
<th>Sequence (5' to 3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>1d</td>
<td>AT...GAGC...</td>
</tr>
<tr>
<td>2</td>
<td>ATGGAAGGTCCAGGCTTC</td>
</tr>
<tr>
<td>2a</td>
<td>CACTC...G...</td>
</tr>
<tr>
<td>2b</td>
<td>ZCTC.ZG.Z...</td>
</tr>
<tr>
<td>2c</td>
<td>ZCTC.ZG.Z...</td>
</tr>
<tr>
<td>2d</td>
<td>ZC...CTC...</td>
</tr>
<tr>
<td>2e</td>
<td>ZC...CTC...</td>
</tr>
<tr>
<td>3</td>
<td>GAGAAAGCTGGACCTTCAT</td>
</tr>
<tr>
<td>3a</td>
<td>A...A...</td>
</tr>
<tr>
<td>3b</td>
<td>A...A...C...</td>
</tr>
<tr>
<td>3c</td>
<td>C...A...</td>
</tr>
<tr>
<td>3d</td>
<td>Z...Z...</td>
</tr>
<tr>
<td>3e</td>
<td>Z...Z...</td>
</tr>
<tr>
<td>3f</td>
<td>A...A...</td>
</tr>
<tr>
<td>3g</td>
<td>A...A...CC.G.ACTG..</td>
</tr>
<tr>
<td>3M</td>
<td>TTCATGCGATCTGATGCT</td>
</tr>
<tr>
<td>3Ma</td>
<td>CT...</td>
</tr>
<tr>
<td>3Mb</td>
<td>Z...Z...</td>
</tr>
<tr>
<td>3Mc</td>
<td>Z...Z...</td>
</tr>
<tr>
<td>3Md</td>
<td>A...A...</td>
</tr>
<tr>
<td>3Me</td>
<td>C...A...</td>
</tr>
<tr>
<td>4</td>
<td>TCAAGTT</td>
</tr>
<tr>
<td>4a</td>
<td>GC...</td>
</tr>
<tr>
<td>4b</td>
<td>GCG...</td>
</tr>
<tr>
<td>4c</td>
<td>TGAA...</td>
</tr>
<tr>
<td>4d</td>
<td>TTAA...</td>
</tr>
<tr>
<td>4e</td>
<td>Residue 2-8 of ---AAA---</td>
</tr>
<tr>
<td>4f</td>
<td>C...AAA</td>
</tr>
<tr>
<td>4g</td>
<td>Residue 11-18 of ---AAA--CT</td>
</tr>
<tr>
<td>4h</td>
<td>AAA...C</td>
</tr>
<tr>
<td>LPS</td>
<td>7.8 ± 2.5 4.8 ± 1.6</td>
</tr>
</tbody>
</table>

'Stimulation indexes are the means and std. dev. derived from at least 3 separate experiments, and are compared to wells cultured with no added ODN. ND = not done. Cpg dinucleotides are underlined. Dots indicate identity; dashes indicate deletions. Z indicates 5 methyl cytosine.'
<table>
<thead>
<tr>
<th>ODN</th>
<th>SEQUENCE (5'→3')</th>
<th>IL-6 (pg/ml)</th>
<th>CH12.LX</th>
<th>SPLENIC B CELL</th>
<th>ST1</th>
<th>IgM (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>512</td>
<td>(SEQ ID: No:20)</td>
<td>TCCATCGGCGCTGAGTG</td>
<td>1300 ± 106</td>
<td>627 ± 43</td>
<td>5.0 ± 0.3</td>
<td>7315 ± 1324</td>
</tr>
<tr>
<td>1637</td>
<td>(SEQ ID: No:29)</td>
<td>………………CA………………</td>
<td>136 ± 27</td>
<td>46 ± 6</td>
<td>1.7 ± 0.2</td>
<td>770 ± 72</td>
</tr>
<tr>
<td>1615</td>
<td>(SEQ ID: No:101)</td>
<td>………………G………………</td>
<td>1201 ± 150</td>
<td>850 ± 202</td>
<td>3.7 ± 0.3</td>
<td>3212 ± 617</td>
</tr>
<tr>
<td>1614</td>
<td>(SEQ ID: No:102)</td>
<td>………………A………………</td>
<td>1533 ± 321</td>
<td>1812 ± 103</td>
<td>10.4 ± 0.6</td>
<td>7558 ± 414</td>
</tr>
<tr>
<td>1636</td>
<td>(SEQ ID: No:103)</td>
<td>………………AA………………</td>
<td>1131 ± 76</td>
<td>947 ± 132</td>
<td>5.4 ± 0.4</td>
<td>3983 ± 485</td>
</tr>
<tr>
<td>1634</td>
<td>(SEQ ID: No:104)</td>
<td>………………AT………………</td>
<td>1049 ± 223</td>
<td>1671 ± 175</td>
<td>9.2 ± 0.9</td>
<td>6256 ± 261</td>
</tr>
<tr>
<td>1619</td>
<td>(SEQ ID: No:105)</td>
<td>………………TA………………</td>
<td>1555 ± 304</td>
<td>2908 ± 129</td>
<td>12.5 ± 1.0</td>
<td>8243 ± 690</td>
</tr>
<tr>
<td>1618</td>
<td>(SEQ ID: No:7)</td>
<td>………………TT………………</td>
<td>2109 ± 291</td>
<td>2596 ± 166</td>
<td>12.9 ± 0.7</td>
<td>10425 ± 674</td>
</tr>
<tr>
<td>1639</td>
<td>(SEQ ID: No:3)</td>
<td>………………GG………………</td>
<td>1827 ± 83</td>
<td>2012 ± 132</td>
<td>11.5 ± 0.4</td>
<td>9489 ± 103</td>
</tr>
<tr>
<td>1707</td>
<td>(SEQ ID: No:88)</td>
<td>………………TC………………</td>
<td>ND</td>
<td>1147 ± 175</td>
<td>4.0 ± 0.2</td>
<td>3534 ± 217</td>
</tr>
<tr>
<td>1708</td>
<td>(SEQ ID: No:106)</td>
<td>………………TG………………</td>
<td>ND</td>
<td>59 ± 3</td>
<td>1.5 ± 0.1</td>
<td>466 ± 109</td>
</tr>
</tbody>
</table>

Dots indicate identity; Cpg dinucleotides are underlined; ND = not done

The experiment was done at least three times with similar results. The level of IL-6 of unstimulated control cultures of both CH12.LX and splenetic B cells was ≤ 10 pg/ml. The IgM level of unstimulated culture was 547 ± 82 ng/ml. Cpg dinucleotides are underlined and dots indicate identity.

[^2]: Uridine uptake was indicated as a fold increase (SI: stimulation index) from unstimulated control (2332.87 ± 213.68 umol). Cells were stimulated with 20 μM of various Cpg O-ODN. Data present the mean ± SD of triplicates.

[^3]: Measured by ELISA.

The kinetics of lymphocyte activation were investigated using mouse spleen cells. When the cells were pulsed at the same time as ODN addition and harvested just four hours later, there was already a two-fold increase in [3H] uridine incorporation. Stimulation peaked at 12-48 hours and then decreased. After 24 hours, no intact ODN were detected, perhaps accounting for the subsequent fall in stimulation when purified B cells with or without anti-IgM (at a sub-mitogenic dose) were cultured with Cpg ODN, proliferation was found to synergistically increase about 10-fold by the two mitogens in combination after 48 hours. The magnitude of stimulation was concentration dependent and consistently exceeded that of LPS under optimal conditions for both. Oligonucleotides containing a nucleoside resistant phosphothioate backbone were approximately two hundred times more potent than unmodified oligonucleotides.

Cell cycle analysis was used to determine the proportion of B cells activated by Cpg-ODN. Cpg-ODN induced cycling in more than 95% of B cells. Splenic B lymphocytes sorted by flow cytometry into CD23- (marginal zone) and CD23+ (follicular) subpopulations were equally responsive to ODN- induced stimulation, as were both resting and activated populations of B cells isolated by fractionation over Percoll gradients. These studies demonstrated that Cpg-ODN induce essentially all B cells to enter the cell cycle.

Immunostimulatory Nucleic Acid Molecules Block Murine B Cell Apoptosis

Certain B cell lines, such as WEHI-231, are induced to undergo growth arrest and/or apoptosis in response to crosslinking of their antigen receptor by anti-IgM (Jakway, J. P. et al., "Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide and other bacterial products" J. Immunol. 137: 2225 (1986); Tsubata, T., J. Wu and T. Honjo: B-cell apoptosis induced by T-antigen receptor crosslinking is blocked by a T-cell signal through CD40." Nature 364: 645 (1993).) WEHI-231 cells are rescued from this growth arrest by certain stimuli such as LPS and by the CD40 ligand. ODN containing the Cpg motif were also found to protect WEHI-231 from anti-IgM induced growth arrest, indicating that accessory cell populations are not required for the effect. Subsequent work indicates that Cpg ODN induce Bcl-x and myc expression, which may account for the protection from apoptosis. Also, Cpg nucleic acids have been found to block apoptosis in human cells. This inhibition of apoptosis is important, since it should enhance and prolong immune activation by Cpg DNA.

Identification of the optimal Cpg motif for induction of Murine IL-6 and IgM or secretion and B cell proliferation

To evaluate whether the optimal B cell stimulatory Cpg motif was identical with the optimal Cpg motif for IL-6 secretion, a panel of ODN in which the bases flanking the Cpg dinucleotide were progressively substituted was studied. This ODN panel was analyzed for effects on B cell proliferation, Ig production, and IL-6 secretion, using both splenic B cells and CH12.LX cells. As shown in Table 2, the optimal stimulatory motif contains an unmethylated Cpg flanked by two 5' purines and two 3' pyrimidines. Generally a mutation of either 5' purine to pyrimidine or 3' pyrimidine to pyrimidine significantly reduced its effects. Changes in 5' purines to C were especially deleterious, but changes in 5' purines to T or 3' pyrimidines to purines had less marked effects. Based on analyses of these and scores of other ODN, it was determined that the optimal Cpg motif for induction
of IL-6 secretion is TGACGTG, which is identical with the optimal mitogenic and IgM-inducing CpG motif (Table 2). This motif was more stimulatory than any of the palindrome containing sequences studied (1639, 1707 and 1708).

Induction of Murine Cytokine Secretion by CpG motifs in Bacterial DNA or Oligonucleotides

As described in Example 9, the amount of IL-6 secreted by spleen cells after CpG DNA stimulation was measured by ELISA. T cell depleted spleen cell cultures rather than whole spleen cells were used for in vitro studies following preliminary studies showing that T cells contribute little or nothing to the IL-6 produced by CpG DNA-stimulated spleen cells. As shown in Table 3, IL-6 production was markedly increased in cells cultured with E. coli DNA but not in cells cultured with calf thymus DNA. To confirm that the increased IL-6 production observed with E. coli DNA was not due to contamination by other bacterial products, the DNA was digested with Dnase prior to analysis. Dnase pretreatment abolished IL-6 production induced by E. coli DNA (Table 3). In addition, spleen cells from LPS-nonresponsive C3H/HeJ mouse produced similar levels of IL-6 in response to bacterial DNA. To analyze whether the IL-6 secretion induced by E. coli DNA was mediated by the unmethylated CpG dinucleotides in bacterial DNA, methylated E. coli DNA and a panel of synthetic ODN were examined. As shown in Table 3, CpG ODN significantly induced IL-6 secretion (ODN 5a, 5b, 5c) while CpG methylated E. coli DNA, or ODN containing methylated CpG (ODN 5f) or no CpG (ODN 5d) did not. Changes at sites other than CpG dinucleotides (ODN 5b) or methylation of other cytosines (ODN 5g) did not reduce the effects of CpG ODN. Methylation of a single CpG in an ODN with three CpGs resulted in a partial reduction in the stimulation (compare ODN 5c to 5e; Table 3).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>IL-6 (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>calf thymus DNA</td>
<td>≤10</td>
</tr>
<tr>
<td>calf thymus DNA + Dnase</td>
<td>≤10</td>
</tr>
<tr>
<td>E. coli DNA</td>
<td>1169.5 ± 94.1</td>
</tr>
<tr>
<td>E. coli DNA + Dnase</td>
<td>≤10</td>
</tr>
<tr>
<td>CpG methylated E. coli DNA</td>
<td>≤10</td>
</tr>
<tr>
<td>LPS</td>
<td>280.1 ± 17.1</td>
</tr>
<tr>
<td>Media (no DNA)</td>
<td>≤10</td>
</tr>
</tbody>
</table>

T cell depleted spleen cells from mice were stimulated with phosphodiester modified oligonucleotides (ODN 5f) or CsCl-purified calf thymus DNA (50 µg/ml) or E. coli DNA (50 µg/ml) with or without enzyme treatment, or LPS (10 µg/ml) for 24 hr. Data represent the mean (pg/ml) ± SD of triplicates. CpG dinucleotides are underlined and dots indicate identity. Z indicates 5-methylcytosine.

CpG motifs can be used as an artificial adjuvant

Non-specific stimulators of the immune response are known as adjuvants. The use of adjuvants is essential to induce a strong antibody response to soluble antigens (Harlow and Lane, Antibodies: A Laboratory manual, Cold Spring Harbor, N.Y. Current Edition; hereby incorporated by reference). The overall effect of adjuvants is dramatic and their importance cannot be overemphasized. The action of an adjuvant allows much smaller doses of antigen to be used and generates antibody responses that are more persistent. The non-specific activation of the immune response often can spell the difference between success and failure in obtaining an immune response. Adjuvants should be used for first injections unless there is some very specific reason to avoid this. Most adjuvants incorporate two components. One component is designed to protect the antigen from rapid catabolism (e.g., liposomes or synthetic surfactants (Hunter et al. 1981)). Liposomes are only effective when the immunogen is incorporated into the outer lipid layer; entrapped molecules are not seen by the immune system. The other component is a substance that will stimulate the immune response nonspecifically. These substances act by raising the level of lymphokines. Lymphokines stimulate the activity of antigen-processing cells directly and cause a local inflammatory reaction at the site of injection. Early work relied entirely on heat-killed bacteria (Dienes 1936) or lipopolysaccharide (LPS) (Johnson et al. 1956). LPS is reasonably toxic, and, through analysis of its structural components, most of its properties as an adjuvant have been shown to be in a portion known as lipid A. Lipid A is available in a number of synthetic and natural forms that are much less toxic than LPS, but still retains much of the better adjuvant properties of parental LPS molecule. Lipid A compounds are often delivered using liposomes.

Recently an intense drive to find potent adjuvants with more acceptable side effects has led to the production of new synthetic adjuvants. The present invention provides the sequence 1826 TCCATGACGTTTCTGGAGTTC (SEQ ID NO: 10), which is an adjuvant including CpG containing nucleic acids. The sequence is a strong immune activating sequence and is a super adjuvant, with efficacy comparable or superior to complete Freund’s, but without apparent toxicity.

Titrations of Induction of Murine IL-6 Secretion by CpG motifs

Bacterial DNA and CpG ODN induced IL-6 production in T cell depleted murine spleen cells in a dose-dependent...
manner, but vertebrate DNA and non-CpG ODN did not (FIG. 1). IL-6 production plateaued at approximately 50 µg/ml of bacterial DNA or 40 µM of CpG O-ODN. The maximum levels of IL-6 induced by bacterial DNA and CpG ODN were 1–1.5 ng/ml and 2–4 ng/ml respectively. These levels were significantly greater than those seen after stimulation by LPS (0.35 ng/ml) (FIG. 1A). To evaluate whether CpG ODN with a nuclease-resistant DNA backbone would also induce IL-6 production, S-ODN were added to T cell depleted murine spleen cells. CpG S-ODN also induced IL-6 production in a dose-dependent manner to approximately 9 ng/ml in the CpG S-ODN injected group (FIG. 2). IL-6 protein in sera rapidly decreased after 4 hr and returned to basal level by 12 hr after stimulation. In contrast to CpG DNA stimulated groups, no significant increase of IL-6 was observed in the sera from the non-stimulatory S-ODN or PBS injected groups (FIG. 2).

Tissue distribution and kinetics of IL-6 mRNA expression induced by CpG motifs in vivo

As shown in FIG. 2, the level of serum IL-6 increased rapidly after CpG DNA stimulation. To investigate the possible tissue origin of this serum IL-6, and the kinetics of IL-6 gene expression in vivo after CpG DNA stimulation, BALB/c mice were injected iv. with CpG or non-CpG S-ODN and RNA was extracted from liver, spleen, thymus, and bone marrow at various time points after stimulation. As shown in FIG. 3A, the level of IL-6 mRNA in liver, spleen, and thymus was increased within 30 min. after injection of CpG S-ODN. The liver IL-6 mRNA peaked at 2 hr post-injection and rapidly decreased and reached basal level 8 hr after stimulation (FIG. 3A). Splenic IL-6 mRNA peaked at 2 hr after stimulation and then gradually decreased (FIG. 3A). Thymus IL-6 mRNA peaked at 1 hr post-injection and then gradually decreased (FIG. 3A). IL-6 mRNA was significantly increased in bone marrow within 1 hr after CpG S-ODN injection but then returned to basal level. In response to CpG S-ODN, liver, spleen and thymus showed more substantial increases in IL-6 mRNA expression than the bone marrow.

Patterns of Murine Cytokine Expression Induced by CpG DNA

In vivo or in whole spleen cells, no significant increase in the protein levels of the following interleukins: IL-2, IL-3, IL-4, IL-5, or IL-10 was detected within the first six hours (Klinman, D. M. et al., (1996) Proc. Natl. Acad. Sci. USA 93:2879–2883). However, the level of TNF-α is increased within 30 minutes and the level of IL-6 increased strikingly within 2 hours in the serum of mice injected with CpG ODN. Increased expression of IL-12 and interferon gamma (IFN-γ) mRNA by spleen cells was also detected within the first two hours.

TABLE 5

<table>
<thead>
<tr>
<th>ODN</th>
<th>Sequence (5’→3’)</th>
<th>IL-6</th>
<th>TNF-α</th>
<th>IFN-γ</th>
<th>GM-CSF</th>
<th>IL-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>512</td>
<td>TCCATGCATCGGTCTCTATGCTT</td>
<td>500</td>
<td>140</td>
<td>15.6</td>
<td>70</td>
<td>250</td>
</tr>
<tr>
<td>SEQ ID NO:28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1637</td>
<td>TATGCTCTCTATGCTT</td>
<td>550</td>
<td>16</td>
<td>7.8</td>
<td>15.6</td>
<td>16</td>
</tr>
<tr>
<td>SEQ ID NO:29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1615</td>
<td>TATGCTCTCTATGCTT</td>
<td>600</td>
<td>145</td>
<td>7.8</td>
<td>45</td>
<td>145</td>
</tr>
<tr>
<td>SEQ ID NO:101</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ODN</td>
<td>Sequence (5’–3’)</td>
<td>IL-6</td>
<td>TNF-α</td>
<td>IFN-γ</td>
<td>GM-CSF</td>
<td>IL-12</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>1614</td>
<td><em><strong><strong>A</strong></strong></em>____</td>
<td>550</td>
<td>31</td>
<td>0</td>
<td>50</td>
<td>31</td>
</tr>
<tr>
<td>SEQ ID: NO:102</td>
<td><em><strong><strong>A</strong></strong></em>____</td>
<td>325</td>
<td>250</td>
<td>35</td>
<td>40</td>
<td>250</td>
</tr>
<tr>
<td>1636</td>
<td><em><strong><strong>T</strong></strong></em>____</td>
<td>300</td>
<td>400</td>
<td>85</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>SEQ ID: NO:103</td>
<td><em><strong><strong>C</strong></strong></em>____</td>
<td>275</td>
<td>450</td>
<td>200</td>
<td>80</td>
<td>450</td>
</tr>
<tr>
<td>1689</td>
<td><em><strong><strong>T</strong></strong></em>____</td>
<td>300</td>
<td>60</td>
<td>15.6</td>
<td>15.6</td>
<td>62</td>
</tr>
<tr>
<td>SEQ ID: NO:7</td>
<td><em><strong><strong>A</strong></strong></em>____</td>
<td>625</td>
<td>220</td>
<td>15.6</td>
<td>40</td>
<td>220</td>
</tr>
<tr>
<td>1707</td>
<td><em><strong><strong>A</strong></strong></em>____</td>
<td>300</td>
<td>70</td>
<td>17</td>
<td>0</td>
<td>70</td>
</tr>
<tr>
<td>1708</td>
<td><em><strong><strong>A</strong></strong></em>____</td>
<td>270</td>
<td>10</td>
<td>17</td>
<td>ND</td>
<td>10</td>
</tr>
</tbody>
</table>

Dots indicate identity; CpG dinucleotides are underlined.

*measured by ELISA using Quantikine kits from R&D Systems (pg/ml). Cells were cultured in 10% autologous serum with the indicated oligodeoxynucleotides (12 µg/ml) for 4 hr in the case of TNF-α or 24 hr for the other cytokines before supernatant harvest and assay. Data are presented as the level of cytokine above that in wells with no added oligodeoxynucleotide.

**CpG DNA induces cytokine secretion by human PBMC, specifically monocytes.**

The same panels of ODN used for studying mouse cytokine expression were used to determine whether human cells also are induced by CpG motifs to express cytokine (or proliferate), and to identify the CpG motif(s) responsible. Oligonucleotide 1619 (GTGGTT; residues 6–11 of SEQ ID NO: 105) was the best inducer of TNF-α and IFN-γ secretion, and was closely followed by a nearly identical motif in oligonucleotide 1634 (GTCGCT; residues 6–11 of SEQ ID NO:104) (Table 5). The motifs in oligodeoxynucleotides 1637 and 1614 (GCCCGT; residues of SEQ ID NO:29 and GACGGT; residues 6–11 of SEQ ID NO:102) led to strong IL-6 secretion with relatively little induction of other cytokines. Thus, it appears that human lymphocytes, like murine lymphocytes, secrete cytokines differentially in response to CpG dinucleotides, depending on the surrounding bases. Moreover, the motifs that stimulate murine cells best differ from those that are most effective with human cells. Certain CpG oligodeoxynucleotides are poor at activating human cells (oligodeoxynucleotides 1707, 1708, which contain the palindromic forming sequences GACGTC; residues 6–11 of SEQ ID NO:8 and CACGTT; residues 6–11 of SEQ ID NO:106 respectively).

The cells responding to the DNA appear to be monocytes, since the cytokine secretion is abolished by treatment of the cells with L-leucyl-L-leucine methyl ester (L-LME), which is selectively toxic to monocytes (but also to cytotoxic T lymphocytes and NK cells), and does not affect B cell Ig secretion (Table 6). The cells surviving L-LME treatment had >95% viability by trypan blue exclusion, indicating that the lack of a cytokine response among these cells did not simply reflect a nonspecific death of all cell types. Cytokine secretion in response to E. coli (EC) DNA requires unmethylated CpG motifs, since it is abolished by methylation of the EC DNA (next to the bottom row, Table 6). LPS contamination of the DNA cannot explain the results since the level of contamination was identical in the native and methylated DNA, and since addition of twice the highest amount of contaminating LPS had no effect (not shown).

<table>
<thead>
<tr>
<th>DNA</th>
<th>TNF-α (pg/ml)</th>
<th>IL-6 (pg/ml)</th>
<th>IFN-γ (pg/ml)</th>
<th>RANTES (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC DNA (50 µg/ml)</td>
<td>900</td>
<td>12,000</td>
<td>700</td>
<td>1560</td>
</tr>
<tr>
<td>EC DNA (5 µg/ml)</td>
<td>850</td>
<td>11,000</td>
<td>400</td>
<td>750</td>
</tr>
<tr>
<td>EC DNA (0.5 µg/ml)</td>
<td>500</td>
<td>ND</td>
<td>200</td>
<td>0</td>
</tr>
<tr>
<td>EC DNA (0.05 µg/ml)</td>
<td>62.5</td>
<td>10,000</td>
<td>15.6</td>
<td>0</td>
</tr>
<tr>
<td>EC DNA (50 µg/ml) + L-LME</td>
<td>0</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>EC DNA (10 µg/ml) Methyl.</td>
<td>0</td>
<td>5</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>CT DNA (50 µg/ml)</td>
<td>0</td>
<td>600</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

1Levels of all cytokines were determined by ELISA using Quantikine kits from R&D Systems as described in the previous table. Results are representative using PBMC from different donors.
2Cells were pre-treated for 15 min. with L-leucyl-L-leucine methyl ester (M-LME) to determine whether the cytokine production under these conditions was from monocytes or other L-LME-sensitive cells.
3EC DNA was methylated using 2U/kg DNA of CpG methylase (New England Biolabs) according to the manufacturer’s directions, and methylation confirmed by digestion with Hpa-II and Msp-I. As a negative control, samples were included containing twice the maximal amount of LPS contained in the highest concentration of EC DNA which failed to induce detectable cytokine production under these experimental conditions. ND = not done.

The loss of cytokine production in the PBMC treated with L-LME suggested that monocytes may be responsible for cytokine production in response to CpG DNA. To test this hypothesis more directly, the effects of CpG DNA on highly purified human, monocytes and macrophages was tested. As hypothesized, CpG DNA directly activated production of the cytokines IL-6, GM-CSF, and TNF-α by human macrophages, whereas non-CpG DNA did not (Table 7).

<table>
<thead>
<tr>
<th>DNA</th>
<th>IL-6 (pg/ml)</th>
<th>GM-CSF (pg/ml)</th>
<th>TNF-α (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cells alone</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CT DNA (50 µg/ml)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EC DNA (50 µg/ml)</td>
<td>2000</td>
<td>15.6</td>
<td>1000</td>
</tr>
</tbody>
</table>
Biological Role of IL-6 in Inducing Murine IgM Production in Response to CpG Motifs

The kinetic studies described above revealed that induction of IL-6 secretion, which occurs within 1 hr post CpG stimulation, precedes IgM secretion. Since the optimal CpG motif for ODN inducing secretion of IL-6 is the same as that for IgM (Table 2), whether the CpG motifs independently induce IgM and IL-6 production or whether the IgM production is dependent on prior IL-6 secretion was examined. The addition of neutralizing anti-IL-6 antibodies inhibited in vitro IgM production mediated by CpG ODN in a dose-dependent manner but a control antibody did not (Fig. 4A). In contrast, anti-IL-6 addition did not affect either the basal level or the CpG-induced B cell proliferation (Fig. 4B).

Increased transcriptional activity of the IL-6promoter in response to CpG DNA

The increased level of IL-6 mRNA and protein after CpG DNA stimulation could result from transcriptional or post-transcriptional regulation. To determine if the transcriptional activity of the IL-6 promoter was upregulated in B cells cultured with CpG ODN, a murine B cell line, WEHI-231, which produces IL-6 in response to CpG DNA, was transfected with an IL-6 promoter-CAT construct (pIL-6-CAT) (Potratz, S. T. et al., 1978) which inhibits expression of human interleukin-6-promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 93:944-954 CAT assays were performed after stimulation with various concentrations of CpG ODN or non-CpG ODN. As shown in Fig. 5, CpG ODN induced increased CAT activity in a dose-dependent manner while non-CpG ODN failed to induce CAT activity. This confirms that CpG induces the transcriptional activity of the IL-6 promoter.

Dependence of B cell activation by CpG ODN on the Number of 5' and 3' Phosphorothioate Internucleotide Linkages

To determine whether partial sulfur modification of the ODN backbone would be sufficient to enhance B cell activation, the effects of a series of ODN with the same sequence, but with differing numbers of S internucleotide linkages at the 5' and 3' ends were tested. Based on previous studies of nuclease degradation of ODN, it was determined that at least two phosphorothioate linkages at the 5' end of ODN were required to provide optimal protection of the ODN from degradation by intracellular exonucleases. Only chimeric ODN containing two 5' phosphorothioate-modified linkages, and a variable number of 3' modified linkages were therefore examined.

The lymphocyte stimulating effects of these ODN were tested at three concentrations (3.3, 10, and 30 μM) by measuring the total levels of RNA synthesis (by 3H uridine incorporation) or DNA synthesis (by 3H thymidine incorporation) in treated splen cell cultures (Example 10). O-ODN (50% phosphorothioate modifications) bearing a CpG motif caused no spleen cell stimulation unless added to the cultures at concentrations of at least 10 μM (Example 10). However, when this sequence was modified with two S linkages at the 5' end and at least three S linkages at the 3' end, significant stimulation was seen at a dose of 3.3 μM. At this low dose, the level of stimulation showed a progressive increase as the number of 3' modified bases was increased, until this reached or exceeded six, at which point the stimulation index began to decline. In general, the optimal number of 3' S linkages for spleen cell stimulation was five. Of all three concentrations tested in these experiments, the S-ODN was less stimulatory than the optimal chimeric compounds.

Dependence of CpG-mediated lymphocyte activation on the type of backbone modification

Phosphorothioate modified ODN (S-ODN) are far more nuclease resistant than phosphodiester modified ODN (O-ODN). Thus, the increased immune stimulation caused by S-ODN and S-O-ODN (i.e., chimeric phosphorothioate ODN in which the central linkages are phosphodiester, but the two 5' and five 3' linkages are phosphorothioate modified) compared to O-ODN may result from the nuclease resistance of the former. To determine the role of ODN nuclease resistance in immune stimulation by CpG ODN, the stimulatory effects of chimeric ODN in which the 5' and 3' ends were rendered nuclease resistant with either methylphosphonate (MP-), methylphosphorothioate (MPS-), phosphorothioate (S-), or phosphorothiothioate (SS-) internucleotide linkages were tested (Example 10). These studies showed that despite their nuclease resistance, MP-O-ODN were actually less immune stimulatory than O-ODN. However, combining the MP and S modifications by replacing both nonbridging O molecules with 5' and 3' MPS internucleotide linkages restored immune stimulation to a slightly higher level than that triggered by O-ODN.

S-O-ODN were far more stimulatory than O-ODN, and were even more stimulatory than S-ODN, at least at concentrations above 3.3 μM. At concentrations below 3 μM, the S-ODN with the 3M sequence was more potent than the corresponding S-O-ODN, while the S-ODN with the 3D sequence was less potent than the corresponding S-O-ODN (Example 10). In comparing the stimulatory CpG motifs of these two sequences, it was noted that the 3D sequence is a perfect match for the stimulatory motif in that the CpG is flanked by only two 5' purines and two 3' pyrimidines. However, the bases immediately flanking the CpG in ODN 3D are not optimal; it has a 5' pyrimidine and a 3' purine. Based on further testing, it was found that the sequence requirement for immune stimulation is more stringent for S-ODN than for S-O- or O-ODN. S-ODN with poor matches to the optimal CpG motif cause little or no lymphocyte activation (e.g. Sequence 5), whereas a S-O-ODN with good matches to the motif, most critically at the positions immediately flanking the CpG, are more potent than the corresponding S-O-ODN (e.g. Sequence 3M, Sequences 4 and 6), even though at higher concentrations (greater than 3 μM) the peak effect from the S-O-ODN is greater (Example 10).

S-SS-O-ODN were remarkably stimulatory, and caused substantially greater lymphocyte activation than the corresponding S-O-ODN or S-O-ODN at every tested concentration.

The increased B cell stimulation seen with CpG ODN bearing S or SS substitutions could result from any or All of the following effects: nuclease resistance, increased cellular uptake, increased protein binding, and altered intracellular localization. However, nuclease resistance can not be the only explanation, since the MP-O-ODN were actually less stimulatory than the O-ODN with CpG motifs. Prior studies have shown that ODN uptake by lymphocytes is markedly affected by the backbone chemistry (Zhao et al., 1993). Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.
(Antisense Research and Development 3, 53–66; Zhao et al., 1994) Stage specific oligonucleotide uptake in murine bone marrow B cells precursors. Blood 84, 3660–3666.) The highest cell membrane binding and uptake was seen with S-ODN, followed by S-O-ODN, O-ODN, and MP-ODN. This differential uptake correlates well with the degree of immune stimulation.

Unmethylated CpG Containing Oligos Have NK Cell Stimulatory Activity

Experiments were conducted to determine whether CpG containing oligonucleotides stimulated the activity of natural killer (NK) cells in addition to B cells. As shown in Table 8, a marked induction of NK activity among spleen cells cultured with CpG ODN 1 and 3Dd was observed. In contrast, there was relatively no induction in effectors that had been treated with non-CpG control ODN.

| TABLE 8 |
| Induction Of NK Activity By CpG Oligodeoxynucleotides (ODN) |
| % YAC-1 Specific Lysis* Effector: Target | % 2C11 Specific Lysis Effector: Target |
| ODN | 50:1 | 100:1 | 50:1 | 100:1 |
| None | –1.1 | –1.4 | 15.3 | 16.6 |
| 1 | 16.1 | 24.5 | 38.7 | 47.2 |
| 3Dd | 17.1 | 27.0 | 37.0 | 40.0 |
| non-CpG ODN | –1.8 | –1.7 | 14.8 | 15.4 |

Induction of NK activity by DNA containing CpG motifs, but not by non-CpG DNA

Bacterial DNA cultured for 18 hrs. at 37° C. and then assayed for killing of K562 (human) or Yac-1 (mouse) target cells induced NK lytic activity in both mouse spleen cells depleted of B cells and human PBMC, but vertebrate DNA did not (Table 9). To determine whether the stimulatory activity of bacterial DNA may be a consequence of its increased level of unmethylated CpG dinucleotides, the activating properties of more than 50 synthetic ODN containing unmethylated, methylated, or no CpG dinucleotides was tested. The results, summarized in Table 9, demonstrate that synthetic ODN can stimulate significant NK activity, as long as they contain at least one unmethylated CpG dinucleotide. No difference was observed in the stimulatory effects of ODN in which the CpG was within a palindromic (such as ODN 1585, which contains the palindromic AACGTT) from those ODN without palindromes (such as 1613 or 1619), with the caveat that optimal stimulation was generally seen with ODN in which the CpG was flanked by two 5' purines or a 5' CpG dinucleotide and two 3' pyrimidines. Kinetic experiments demonstrated that NK activity peaked around 18 hrs. after addition of the ODN. The data indicates that the murine NK response is dependent on the prior activation of monocytes by CpG DNA, leading to the production of IL-12, TNF-α, and IFN-γ (Example 11).

| TABLE 9 |
| Induction of NK Activity by DNA Containing CpG Motifs but not by Non-CpG DNA |
| DNA or Cytokine Added | Mouse Cells | Human Cells |
| Expt. 1 None | 0.00 | 0.00 |
| IL-2 | 16.68 | 15.82 |
| E.Coli DNA | 7.23 | 5.05 |
| Calf thymus DNA | 0.00 | 0.00 |
| Expt. 2 None | 0.00 | 3.28 |
| 1585 ggGgTCACAGGGACgggg (SEQ ID No.12) | 7.38 | 17.98 |
| 1609 cggcgtggtggttaaggg (SEQ ID No.50) | 0.00 | 4.4 |
| Expt. 3 None | 0.00 |
| 1613 ggggACGggtgatcgt (SEQ ID No.42) | 5.22 |
| 1769 cggcgtggtggttaaggg (SEQ ID No.52) | 0.02 | ND |
| 1619 tgcgctgcttgatcgt (SEQ ID No.38) | 3.35 |
| 1675 cggcgtggtggttaaggg (SEQ ID No.53) | 0.11 |

CpG dinucleotides in ODN sequences are indicated by underlying; z indicates methylation. Lower case letters indicate nuclease resistant phosphorothioate modified internucleotide linkages which, in titration experiments, were more than 20 times as potent as non-modified ODN, depending on the flanking bases. Poly G ends (g) were used in some ODN, because they significantly increase the level of ODN uptake.
From all of these studies, a more complete understanding of the immune, effects of CpG DNA has been developed, which is summarized in Fig. 6.

Immune activation by CpG motifs may depend on bases flanking the CpG, and the number and spacing of the CpGs present within an ODN. Although a single CpG in an ideal base context can be a very strong and useful immune activator, superior effects can be seen with ODN containing several CpGs with the appropriate spacing and flanking bases. For activation of murine B cells, the optimal CpG motif is TCAAGGTT; residues 10–17 of SEQ ID NO:70.

The following studies were conducted to identify optimal ODN sequences for stimulation of human cells by examining the effects of changing the number, spacing, and flanking bases of CpG dinucleotides.

Identification of phosphorothioate ODN with optimal CpG motifs for activation of human NK cells

To have clinical utility, ODN must be administered to a subject in a form that protects them against nuclease degradation. Methods to accomplish this with phosphodiester ODN are well known in the art and include encapsulation in lipids or delivery systems such as nanoparticles. This protection can also be achieved using chemical substitutions to the DNA such as modified DNA backbones including those in which the internucleotide linkages are nuclease resistant. Some modifications may confer additional desirable properties such as increasing cellular uptake. For example, the phosphodiester linkage can be modified via replacement of one of the nonbridging oxygen atoms with a sulfur, which constitutes phosphorothioate DNA. Phosphorothioate ODN have enhanced cellular uptake (Krieg et al., Antisense Res. Dev. 6:133, 1996) and improved B cell stimulation if they also have a CpG motif. Since NK activation correlates strongly with in vivo advantageous effects, the identification of phosphorothioate ODN that will activate human NK cells is very important.

The effects of different phosphorothioate ODNs—containing CpG dinucleotides in various base contexts—human NK activation (Table 10) were examined. ODN 1840, which contained 2 copies of the TGGGCT motif (residues 14–20 of SEQ ID NO:47), had significant NK lytic activity (Table 10). To further identify additional ODNs optimal for NK activation, approximately one hundred ODN containing different numbers and spacing of CpG motifs, were tested with ODN 1982 serving as a control. The results are shown in Table 11.

Effective ODNs began with a TC or TG at the 5' end, however, this requirement was not mandatory. ODNs with internal CpG motifs (e.g. ODN 1840) are generally less potent stimulators than those in which a GTCGCT motif (residues 3–8 of SEQ ID NO:54) immediately follows the 5'th TC (e.g., ODN 1967 and 1968). ODN 1968, which has a second GTCGCT motif (residues 3–8 of SEQ ID NO:46) in its 3' half, was consistently more stimulatory than ODN 1967, which lacks this second motif. ODN 1967, however, was slightly more potent than ODN 1968 in experiments 1 and 3, but not in experiment 2. ODN 2005, which has a third GTCGCT motif (residues 3–8 of SEQ ID NO:46) induced slightly higher NK activity on average than 1968. However, ODN 2006, in which the spacing between the GTCGCT motifs (residues 3–8 of SEQ ID NO:46) was increased by the addition of two Ts between each motif, was superior to ODN 2005 and to ODN 2007, in which only one of the motifs had the addition of the spacing two Ts. The minimal acceptable spacing between CpG motifs is one nucleotide as long as the ODN has two pyrimidines (preferably T) at the 3' end (e.g., ODN 2015). Surprisingly, joining two GTCGCT motifs (residues 3–8 of SEQ ID NO:46) end to end with a 5'T also created a reasonably strong inducer of NK activity (e.g., ODN 2016). The choice of thymine (T) separating consecutive CpG dinucleotides is not absolute, since ODN 2002 induced appreciable NK activation despite the fact that adenine (A) separated its CpGs (i.e., CGACGT; residues 14–20 of SEQ ID NO:82). It should also be noted that ODNs containing no CpG (e.g., ODN 1982), runs of CpGs, or CpGs in bad sequence contexts (e.g., ODN 2010) had no stimulatory effect on NK activation.

<table>
<thead>
<tr>
<th>Table 10</th>
<th>ODN induction of NK Lytic Activity (LU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODN cells</td>
<td>Sequence (5′-3′)</td>
</tr>
<tr>
<td>1754</td>
<td>ACCATGAGCGCATCTGTTTCCCTCTC</td>
</tr>
<tr>
<td>1758</td>
<td>TCTGCACCGGCGGCCTCCTC</td>
</tr>
<tr>
<td>1761</td>
<td>TACCGCGTGGCGACCTCCTC</td>
</tr>
<tr>
<td>1776</td>
<td>ACCATGAGCGGAGACTTTCTTCCCTC</td>
</tr>
<tr>
<td>1777</td>
<td>ACCATGAGCGGAGACTTTCTTCCCTC</td>
</tr>
<tr>
<td>1778</td>
<td>ACCATGAGCGGAGACTTTCTTCCCTC</td>
</tr>
<tr>
<td>1779</td>
<td>ACCATGAGCGGAGACTTTCTTCCCTC</td>
</tr>
<tr>
<td>1780</td>
<td>ACCATGAGCGGAGACTTTCTTCCCTC</td>
</tr>
<tr>
<td>1781</td>
<td>ACCATGAGCGGAGACTTTCTTCCCTC</td>
</tr>
<tr>
<td>1823</td>
<td>CTCCTGACCTTCTACTGCT</td>
</tr>
<tr>
<td>1824</td>
<td>CAGTTGACGCGGCTC</td>
</tr>
<tr>
<td>1825</td>
<td>CTGCTGAGACTCTGAG</td>
</tr>
<tr>
<td>1828</td>
<td>TGACGGCCGC</td>
</tr>
<tr>
<td>1829</td>
<td>AGATGCTTCTAGCTGCT</td>
</tr>
<tr>
<td>1830</td>
<td>RANDOM SEQUENCE</td>
</tr>
<tr>
<td>1834</td>
<td>TCTCCGCGGGCCTC</td>
</tr>
<tr>
<td>1836</td>
<td>TCCGCGGTGGGCCCTC</td>
</tr>
<tr>
<td>1840</td>
<td>TCCATGCTGTTTCTGCTGCT</td>
</tr>
<tr>
<td>1841</td>
<td>TCATGCTGTTTCTGCTGCT</td>
</tr>
<tr>
<td>1842</td>
<td>TCTGCTGTTTCTGCTGCT</td>
</tr>
<tr>
<td>1851</td>
<td>TCTGCTGTTTCTGCTGCT</td>
</tr>
</tbody>
</table>

1Lytic units (LU) were measured as described (8). Briefly, PBMC were collected from normal donors and spun over Ficoll, then cultured with or without the indicated ODN (which were added to cultures at 6 µg/ml) for 24 hr. Then their ability to lyse 35Cr-labeled K562 cells was determined. The results shown are typical of those obtained with several different normal human donors. This oligo mixture contained a random selection of all 4 bases at each position.
### TABLE 11

<table>
<thead>
<tr>
<th>ODN&lt;sup&gt;1&lt;/sup&gt; cells alone sequence (5′→3′)</th>
<th>SEQ ID NO:</th>
<th>expt. 1</th>
<th>expt. 2</th>
<th>expt. 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1840 TCCATGTCCCTCCCTGTGTTTT</td>
<td>73</td>
<td>2.33</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>1960 TCCATGTCCCTCCCTGTGTTTT</td>
<td>77</td>
<td>ND</td>
<td>0.48</td>
<td>8.99</td>
</tr>
<tr>
<td>1961 TCCATGTCCCTCCCTGTGTTTT</td>
<td>78</td>
<td>4.03</td>
<td>1.23</td>
<td>5.08</td>
</tr>
<tr>
<td>1962 TCCATGTCCCTCCCTGTGTTTT</td>
<td>52</td>
<td>ND</td>
<td>1.60</td>
<td>5.74</td>
</tr>
<tr>
<td>1963 TCCATGTCCCTCCCTGTGTTTT</td>
<td>79</td>
<td>3.42</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>1965 TCCATGTCCCTCCCTGTGTTTT</td>
<td>53</td>
<td>0.46</td>
<td>0.42</td>
<td>3.48</td>
</tr>
<tr>
<td>1966 TCCATGTCCCTCCCTGTGTTTT</td>
<td>75</td>
<td>2.62</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>1967 TCCATGTCCCTCCCTGTGTTTT</td>
<td>54</td>
<td>5.02</td>
<td>1.64</td>
<td>8.32</td>
</tr>
<tr>
<td>1968 TCCATGTCCCTCCCTGTGTTTT</td>
<td>55</td>
<td>3.77</td>
<td>5.26</td>
<td>6.12</td>
</tr>
<tr>
<td>1969&lt;sup&gt;2&lt;/sup&gt; TCCATGTCCCTCCCTGTGTTTT</td>
<td>1.32</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>1982 TCCATGTCCCTCCCTGTGTTTT</td>
<td>79</td>
<td>0.05</td>
<td>ND</td>
<td>0.98</td>
</tr>
<tr>
<td>1990 TCCATGTCCCTCCCTGTGTTTT</td>
<td>80</td>
<td>2.10</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>1991 TCCATGTCCCTCCCTGTGTTTT</td>
<td>81</td>
<td>0.89</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2002 TCCATGTCCCTCCCTGTGTTTT</td>
<td>82</td>
<td>4.02</td>
<td>1.31</td>
<td>9.79</td>
</tr>
<tr>
<td>2005 TCCATGTCCCTCCCTGTGTTTT</td>
<td>47</td>
<td>ND</td>
<td>4.22</td>
<td>12.75</td>
</tr>
<tr>
<td>2006 TCCATGTCCCTCCCTGTGTTTT</td>
<td>56</td>
<td>ND</td>
<td>6.17</td>
<td>12.82</td>
</tr>
<tr>
<td>2007 TCCATGTCCCTCCCTGTGTTTT</td>
<td>49</td>
<td>ND</td>
<td>2.68</td>
<td>9.66</td>
</tr>
<tr>
<td>2008 TCCATGTCCCTCCCTGTGTTTT</td>
<td>56</td>
<td>ND</td>
<td>1.37</td>
<td>8.15</td>
</tr>
<tr>
<td>2010 TCCATGTCCCTCCCTGTGTTTT</td>
<td>83</td>
<td>ND</td>
<td>0.01</td>
<td>0.05</td>
</tr>
<tr>
<td>2012 TCCATGTCCCTCCCTGTGTTTT</td>
<td>48</td>
<td>ND</td>
<td>2.02</td>
<td>11.61</td>
</tr>
<tr>
<td>2013 TCCATGTCCCTCCCTGTGTTTT</td>
<td>84</td>
<td>ND</td>
<td>0.56</td>
<td>5.22</td>
</tr>
<tr>
<td>2014 TCCATGTCCCTCCCTGTGTTTT</td>
<td>60</td>
<td>ND</td>
<td>5.74</td>
<td>10.89</td>
</tr>
<tr>
<td>2015 TCCATGTCCCTCCCTGTGTTTT</td>
<td>51</td>
<td>ND</td>
<td>4.53</td>
<td>10.13</td>
</tr>
<tr>
<td>2016 TCCATGTCCCTCCCTGTGTTTT</td>
<td>85</td>
<td>ND</td>
<td>6.54</td>
<td>8.06</td>
</tr>
</tbody>
</table>

<sup>1</sup>PBMC essentially as described herein. Results are representative of 6 separate experiments; each experiment represents a different donor.  
<sup>2</sup>This is the methylated version of ODN 1840 (SEQ ID NO:63); Z = 5-methyl cytosine at residues 8 and 17; ND is lytic units; ND = not done; CpG dinucleotides are underlined for clarity.

Identification of phosphorothioate ODN with optimal CpG motifs for activation of human B cell proliferation

The ability of a CpG ODN to induce B cell proliferation is a good measure of its adjuvant potential. Indeed, ODN with strong adjuvant effects generally also induce B cell proliferation. To determine whether the optimal CpG ODN for inducing B cell proliferation are the same as those for inducing NK cell activity, similar panels of ODN (Table 12) were tested. The most consistent stimulation appeared with ODN 2006 (Table 12).

### TABLE 12

<table>
<thead>
<tr>
<th>ODN sequence (5′→3′)</th>
<th>SEQ ID NO:</th>
<th>expt. 1</th>
<th>expt. 2</th>
<th>expt. 3</th>
<th>expt. 4</th>
<th>expt. 5</th>
<th>expt. 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>1840 TCCATGTCCCTCCCTGTGTTTT</td>
<td>73</td>
<td>4</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>34</td>
</tr>
<tr>
<td>1941 TCCATGTCCCTCCCTGTGTTTT</td>
<td>74</td>
<td>3</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>
TABLE 12-continued

Induction of human B cell proliferation by Phosphorothioate Cpg ODN

<table>
<thead>
<tr>
<th>ODN sequence (5'→3')</th>
<th>SEQ ID NO:</th>
<th>exp. 1</th>
<th>exp. 2</th>
<th>exp. 3</th>
<th>exp. 4</th>
<th>exp. 5</th>
<th>exp. 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>77</td>
<td>ND</td>
<td>2.0</td>
<td>2.0</td>
<td>3.6</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>78</td>
<td>2</td>
<td>3.9</td>
<td>1.9</td>
<td>3.7</td>
<td>ND</td>
<td>37</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>52</td>
<td>ND</td>
<td>3.8</td>
<td>1.9</td>
<td>3.9</td>
<td>5.4</td>
<td>35</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>79</td>
<td>3</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>53</td>
<td>4</td>
<td>3.7</td>
<td>2.4</td>
<td>4.7</td>
<td>6.0</td>
<td>43</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>54</td>
<td>ND</td>
<td>4.4</td>
<td>2.0</td>
<td>4.5</td>
<td>5.0</td>
<td>36</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>55</td>
<td>ND</td>
<td>4.0</td>
<td>2.0</td>
<td>4.9</td>
<td>8.7</td>
<td>38</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>79</td>
<td>3</td>
<td>1.8</td>
<td>1.3</td>
<td>3.1</td>
<td>3.2</td>
<td>12</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>86</td>
<td>ND</td>
<td>2.7</td>
<td>1.4</td>
<td>4.4</td>
<td>ND</td>
<td>14</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>47</td>
<td>5</td>
<td>3.2</td>
<td>1.2</td>
<td>3.0</td>
<td>7.9</td>
<td>37</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>46</td>
<td>4</td>
<td>4.5</td>
<td>2.2</td>
<td>5.8</td>
<td>8.3</td>
<td>40</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>49</td>
<td>3</td>
<td>4.0</td>
<td>4.2</td>
<td>4.1</td>
<td>ND</td>
<td>22</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>56</td>
<td>ND</td>
<td>3.0</td>
<td>2.4</td>
<td>1.6</td>
<td>ND</td>
<td>12</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>83</td>
<td>ND</td>
<td>1.6</td>
<td>1.9</td>
<td>3.2</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>48</td>
<td>2</td>
<td>2.8</td>
<td>0</td>
<td>3.2</td>
<td>ND</td>
<td>33</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>84</td>
<td>3</td>
<td>2.3</td>
<td>3.1</td>
<td>2.8</td>
<td>ND</td>
<td>7</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>50</td>
<td>3</td>
<td>2.5</td>
<td>4.0</td>
<td>3.2</td>
<td>6.7</td>
<td>14</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>51</td>
<td>5</td>
<td>1.8</td>
<td>2.6</td>
<td>4.5</td>
<td>9.4</td>
<td>1</td>
</tr>
<tr>
<td>TCCGCTTCTCTCTCTCTCTCTCTT</td>
<td>85</td>
<td>ND</td>
<td>1.1</td>
<td>1.7</td>
<td>2.7</td>
<td>7.3</td>
<td>1</td>
</tr>
</tbody>
</table>

*Cells = human spleen cells stored at -70°C after surgical harvest or PBMC collected from normal donors and spun over PicoH. Cells were cultured in 96 well U-bottom microtiter plates with or without the indicated ODN (which were added to cultures at 6 μM). N = 12 experiments. Cells were cultured for 4–7 days, pulsed with 1 μCi of [3H] thymidine for 18 hr before harvest and scintillation counting. Stimulation index = the ratio of cpm in wells without ODN to that in wells that had been stimulated throughout the culture period with the indicated ODN (there were no further additions of ODN after the cultures were set up). ND = not done.

Identification of phosphorothioate ODN that induce human IL-12 secretion

The ability of a CpG ODN to induce IL-12 secretion is a good measure of its adjuvant potential, especially in terms of its ability to induce a Th1 immune response, which is highly dependent on IL-12. Therefore, the ability of a panel of phosphorothioate ODN to induce IL-12 secretion from human PBMC in vitro (Table 13) was examined. These experiments showed that in some human PBMC, most CpG ODN could induce IL-12 secretion (e.g., exp. 1). However, other donors responded to just a few CpG ODN (e.g., exp. 2). ODN 2006 was a consistent inducer of IL2 secretion from most subjects (Table 13).
TABLE 13—continued

<table>
<thead>
<tr>
<th>SEQ</th>
<th>IL-12 (pg/ml)</th>
<th>ID</th>
<th>ext.</th>
<th>ext.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODN1 sequence</td>
<td>5'3'</td>
<td>NO</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2014 TGTGCTGGGTGGTGG</td>
<td>50</td>
<td>28</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2015 TGTGCTGGGTGGTGG</td>
<td>51</td>
<td>14</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2016 TGTGCTGGGTGGTGG</td>
<td>85</td>
<td>3</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

PBMC were collected from normal donors and spun over Ficoll, then cultured at 10^6 cells/well in 96 well microtiter plates with or without the indicated ODN which were added to cultures at 6 µg/ml. Supernatants were collected at 24 hr and tested for IL-12 levels by ELISA as described in methods. A standard curve was run in each experiment, which represents a different donor.

Identification of B cell and monocyte/NK cell-specific oligonucleotides

As shown in FIG. 6, Cpg DNA can directly activate highly purified B cells and monocyte cells. There are many similarities in the mechanism through which Cpg DNA activates these cell types. For example, both require NFκB activation as explained further below.

In further studies of different immune effects of Cpg DNA, it was found that there is more than one type of Cpg motif. Specifically, oligo 1668, with the best mouse B cell motif, is a strong inducer of both B cell and natural killer (NK) cell activation, while oligo 1758 is a weak B cell activator, but still induces excellent NK responses (Table 14).

TABLE 14

<table>
<thead>
<tr>
<th>ODN Sequence</th>
<th>B cell activation</th>
<th>NK activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1668 TCCATGACGCTTCCCTGATCT</td>
<td>(SEQ.ID.NO:17) 42,849</td>
<td>2.52</td>
</tr>
<tr>
<td>1758 TCCCTAGCCTGCGCAT</td>
<td>(SEQ.ID.NO:45) 1,747</td>
<td>6.66</td>
</tr>
<tr>
<td>NONE</td>
<td>367</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Cpg dinucleotides are underlined; oligonucleotides were synthesized with phosphorothioate modified backbones to improve their nuclease resistance. Cpg dinucleotides at a 200 nM concentration as described in Example 1. Measured in lytic units.

Teleological Basis of Immunostimulatory, Nucleic Acids

Vertebrate DNA is highly methylated and Cpg dinucleotides are underrepresented. However, the stimulatory Cpg motif is common in microbial genomic DNA, but quite rare in vertebrate DNA. In addition, bacterial DNA has been reported to induce B cell proliferation 2nd immunoglobulin (Ig) production, while mammalian DNA does not (Messina, J. P. et al., J. Immunol. 147:1759 (1991)). Experiments further described in Example 3, in which methylation of bacterial DNA Cpg motifs was found to abolish mitogenicity, demonstrates that the difference in Cpg status is the cause of B cell stimulation by bacterial DNA. This data supports the following conclusion: that unmethylated Cpg dinucleotides present within bacterial DNA are responsible for the stimulatory effects of bacterial DNA.

Teleologically, it appears likely that lymphocyte activation by the Cpg motif represents an immune defense mechanism that can thereby distinguish bacterial from host DNA. Host DNA, which would commonly be present in many anatomic regions and areas of inflammation due to apoptosis (cell death), would generally induce little or no lymphocyte activation due to Cpg suppression and methylation. However, the presence of bacterial DNA containing unmethylated Cpg motifs can cause lymphocyte activation precisely in infected anatomic regions, where it is beneficial. This novel activation pathway provides a rapid alternative to T cell dependent antigen specific B cell activation. Since the Cpg pathway synergizes with B cell activation through the antigen receptor, B cells bearing antigen receptor specific for bacterial antigens would receive one activation signal through cell membrane Ig and a second signal from bacterial DNA, and would therefore tend to be preferentially activated. The interrelationship of this pathway with other pathways of B cell activation provide a physiologic mechanism employing a polyclonal antigen to induce antigen-specific responses.

However, it is likely that B cell activation would not be totally nonspecific. B cells bearing antigen receptors specific for bacterial products could receive one activation signal through cell membrane Ig, and a second from bacterial DNA, thereby more vigorously triggering antigen specific immune responses. As with other immune defense mechanisms, the response to bacterial DNA could have undesirable consequences in some settings. For example, autoimmune responses to self antigens would also tend to be preferentially triggered by bacterial infections, since autoantigens could also provide a second activation signal to autoreactive B cells triggered by bacterial DNA. Indeed the induction of autoimmunity by bacterial infections is a com-

Unlike antigens that trigger B cells through their surface Ig receptor, CpG-ODN did not induce any detectable Ca^2+ flux, changes in protein tyrosine phosphorylation, or IP 3 generation. Flow cytometry with HTTC-conjugated ODN with or without a CpG motif was performed as described in Zhao, Q. et al., (Antisense Research and Development 3:53–66 (1993)), and showed equivalent membrane binding, cellular uptake, eflux, and intracellular localization. This suggests that there may not be cell membrane proteins specific for CpG ODN. Rather than acting through the cell membrane, that data suggests that unmethylated CpG containing oligonucleotides require cell uptake for activity: ODN covalently linked to a solid Tellon support were nonsimilatory, as were biotinylated ODN immobilized on either avidin beads or avidin coated petri dishes. CpG ODN conjugated to either FITC or biotin retained full mitogenic properties in inducing cell bound to solid support.

Recent data indicate the involvement of the transcription factor NFκB as a direct or indirect mediator of the CpG effect. For example, within 15 minutes of treating B cells or monocytes with CpG DNA, the level of NFκB binding activity is increased (FIG. 7). However, it is not increased by DNA that does not contain CpG motifs. In addition, it was found that two different inhibitors of NFκB activation, PDTC and glucocorticoids, completely block the lymphocyte stimulation by CpG DNA as measured by B cell proliferation or monocytic cell cytokine secretion, suggesting that NFκB activation is required for both cell types.

There are several possible mechanisms through which NFκB can be activated. These include through activation of various protein kinases, or through the generation of reactive oxygen species. No evidence for protein kinase activation induced immediately after CpG DNA treatment of B cells or monocytic cells have been found, and inhibitors of protein kinase A, protein kinase C, and protein tyrosine kinases had no effects on the CpG induced activation. However, CpG DNA causes a rapid induction of the production of reactive oxygen species in both B cells and monocytic cells, as detected by the sensitive fluorescent dye dihydrodihromadine 123 as described in Royall, J. A., and Ischiropoulos, H. (Archives of Biochemistry and Biophysics 302:348–355 (1993)). Moreover, inhibitors of the generation of these reactive oxygen species completely block the induction of NFκB and the later induction of cell proliferation and cytokine secretion by CpG DNA.

Working backwards, the next question was how CpG DNA leads to the generation of reactive oxygen species so quickly. Previous studies by the inventors demonstrated that oligonucleotides and plasmid or bacterial DNA are taken up by cells into endosomes. These endosomes rapidly become activated. This activation step was blocked with specific inhibitors of endosome acidification including chloroquine, monensin, and bafilomycin, which work through different mechanisms. FIG. 8A shows the results from a flow cytometry study using mouse B cells with the dihydrodihromadine 123 dye to determine levels of reactive oxygen species. The dye only sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%. As expected, this level of reactive oxygen species was greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B). The cells treated with the CpG oligo also showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D). However, cells treated with an oligonucleotide with the identical sequence except that the CpG was switched did not show this significant increase in the level of reactive oxygen species (Panel E).

In the presence of chloroquine, the results are very different (FIG. 8B). Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E). This demonstrates that unlike the PMA plus ionomycin, the generation of reactive oxygen species following treatment of B cells with CpG DNA requires that the DNA undergo an acidification step in the endosomes. This is a completely novel mechanism of leukocyte activation. Chloroquine, monensin, and bafilomycin also appear to block the activation of NFκB by CpG DNA as well as the subsequent proliferation and induction of cytokine secretion.

Chronic Immune Activation by CpG DNA and Autoimmune Disorders

B cell activation by CpG DNA synergizes with signals through the B cell receptor. This raises the possibility that DNA-specific B cells may be activated by the concurrent binding of bacterial DNA to their antigen receptor, and by the co-stimulatory CpG-mediated signals. In addition, CpG DNA induces B cells to become resistant to apoptosis, a mechanism thought to be important for preventing immune responses to self antigens, such as DNA. Indeed, exposure to bDNA can trigger anti-DNA Ab production. Given this potential ability of CpG DNA to promote autoimmunity, it is therefore noteworthy that patients with the autoimmune disease systemic lupus erythematosus have persistently elevated levels of circulating plasma DNA which is enriched in hypomethylated CpGIs. These findings suggest a possible role for chronic immune activation by CpG DNA in lupus etiopathogenesis.

A class of medications effective in the treatment of lupus is antimalarial drugs, such as chloroquine. While the therapeutic mechanism of these drugs has been unclear, they are known to inhibit endosomal acidification. Leukocyte activation by CpG DNA is not mediated through binding to a cell surface receptor, but requires cell uptake, which occurs via adsorptive endocytosis into an acidified chloroquine-sensitive intracellular compartment. This suggested the hypothesis that leukocyte activation by CpG DNA may occur in association with acidified endosomes, and might even be pH dependent. To test this hypothesis specific inhibitors of DNA acidification were applied to determine whether B cells or monocytes could respond to CpG DNA if endosomal acidification was prevented.

The earliest leukocyte activation event that was detected in response to CpG DNA is the production of reactive oxygen species (ROS), which is induced within five minutes in primary spleen cells and both B and monocyte cell lines. Inhibitors of endosomal acidification including chloroquine, bafilomycin A1, and monensin, which have different mechanisms of action, blocked the CpG-induced generation of ROS, but had no effect on ROS generation mediated by PMA, or ligation of CD40 or IgM. These studies show that ROS generation is a common event in leukocyte activation through diverse pathways. This ROS generation is generally
independent of endosomal acidification, which is required only for the ROS response to CpG DNA. ROS generation in response to CpG is not inhibited by the NFκB inhibitor gliotoxin, confirming that it is not secondary to NFκB activation.

To determine whether endosomal acidification of CpG DNA was also required for its other immune stimulatory effects were performed. Both LPS and CpG DNA induce similar rapid NFκB activation, increases in proto-oncogene mRNA levels, and cytokine secretion. Activation of NFκB by DNA depends on CpG motifs since it was not induced by bDNA treated with CpG methylase, nor by ODN in which bases were switched to disrupt the CpGs. Supershift experiments using specific antibodies indicated that the activated NFκB complexes included the p50 and p65 components. Not unexpectedly, NFκB activation in LPS- or CpG-treated cells was accompanied by the degradation of IkBα and IkBβ. However, inhibitors of endosomal acidification selectively block all of the CpG-induced but none of the LPS-induced cellular activation events. The very low concentration of chloroquine (<10 μM) that has been determined to inhibit CpG-mediated leukocyte activation is noteworthy since it is well below that required for antimalarial activity and other reported immune effects (e.g., 100–1000 μM). These experiments support the role of a pH-dependent signaling mechanism in mediating the stimulatory effects of CpG DNA.

### TABLE 15

<table>
<thead>
<tr>
<th>Specific blockade of CpG-induced TNF-α and IL-12 expression by inhibitors of endosomal acidification or NFκB activation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhibitors:</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Medium</strong></td>
</tr>
<tr>
<td><strong>CpG</strong></td>
</tr>
<tr>
<td><strong>ODN</strong></td>
</tr>
<tr>
<td><strong>LPS</strong></td>
</tr>
</tbody>
</table>

Excessive immune activation by CpG motifs may contribute to the pathogenesis of the autoimmune disease systemic lupus erythematosus, which is associated with elevated levels of circulating hypomethylated CpG DNA. Chloroquine and related antimalarial compounds are effective therapeutic agents for the treatment of systemic lupus erythematosus and some other autoimmune diseases, although their mechanism of action has been obscure. Our demonstration of the ability of extremely low concentrations of chloroquine to specifically inhibit CpG-mediated leukocyte activation suggests a possible new mechanism for its beneficial effect. It is noteworthy that lupus recurrences are thought to be triggered by microbial infection. Levels of BDNA present in infected tissues can be sufficient to induce a local inflammatory response. Together with the likely role of CpG DNA as a mediator of the sepsis syndrome and other diseases our studies suggest possible new therapeutic applications for antimarial drugs that act as inhibitors of endosomal acidification.

CpG-induced ROS generation could be an incidental consequence of cell activation, or a signal that mediates this activation. The ROS scavenger N-acetylcysteine (NAC) blocks CpG-induced NFκB activation, cytokine production, and B cell proliferation, suggesting a causal role for ROS generation in these pathways. These data are compatible with previous evidence supporting a role for ROS in the activation of NFκB. WEHI-231 B cells (5×10⁵ cells/ml) were preincubated for 30 minutes with or without chloroquine (5 μg/ml [≤10 μM]) or gliotoxin (0.2 μg/ml). Cell aliquots were then cultured as above for 10 minutes in RPMI medium with or without a CpG ODN (1826) or non-CpG ODN (111) at 1 μM or phorbol myristate acetate (PMA) plus ionomycin (iono). Cells were then stained with dihydrorhodamine-123 and analyzed for intracellular ROS production by flow cytometry as described (A. K. Krieg, A.-K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. Koretzky and D. Klinman, Nature 374, 546 (1995); Yi, A.-K., D. M. Klinman, T. L. Martin, S. Matson and A. M. Krieg, J. Immunol., 157, 5394-5402 (1996); Krieg, A. M. J. Lab. Clin. Med., 128, 128-133 (1996)). J774 cells, a monocytic line, showed similar pH-dependent CpG-induced ROS responses. In contrast, CpG DNA did not induce the generation of extracellular ROS, nor any detectable neutrophil ROS. These concentrations of chloroquine (and those used with the other inhibitors of endosomal acidification) prevented acidification of the internalized CpG DNA using fluorescent conjugated ODN as described by Tonkinson, et al., (Nucl. Acids Res. 22, 4268 (1994); A. M. Krieg, In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. Editor, S. Akhtar, CRC Press, Inc., pp. 177 (1995)). At higher concentrations than those required to inhibit endosomal acidification, nonspecific inhibitory effects were observed. Each experiment was performed at least three times with similar results.

While NFκB is known to be an important regulator of gene expression, its role in the transcriptional response to CpG DNA was uncertain. To determine whether this NFκB activation was required for the CpG mediated induction of...
gene expression cells were activated with Cpg DNA in the presence or absence of pyridoxine dithiocarbamate (PDTC), an inhibitor of IkB phosphorylation. These inhibitors of NFkB activation completely blocked the Cpg-induced expression of proteoxygenase and cytokine mRNA and protein, demonstrating the essential role of NFkB as a mediator of these events. None of the inhibitors reduced cell viability under the experimental conditions used in these studies. A J774, a murine monocyte cell line, was cultured in the presence of calf thymus (CT), E. coli (EC), or methylated E. coli (mEC) DNA (methylated with Cpg methylase as described) at 5 μg/ml or a Cpg oligodeoxynucleotide (ODN 1826; Table 15) or a non-Cpg ODN (ODN 1745; TCAATGAGCTTCTCAGTCT; SEQ ID NO:8) at 0.75 μM for 1 hr, following which the cells were lysed and nuclear extracts prepared. A doublestranded ODN containing a consensus NFkB site was 5’ radiolabeled and used as a probe for EMSA essentially as described (J.D. Dignam, R.M. Lebovitz and R.G. Roeder, Nucleic Acids Res. 11, 1475 (1983); M. Briskin, M. Damore, R. Law, G. Lee, P.W. Kincaide, C.H. Sibley, M. Kuchel and R. Wall. Mol. Cell. Biol. 10, 422 (1990)). The position of the p50/p65 heterodimer was determined by supercharging with specific Ab to p65 and p50 (Santa Cruz Biotechnology, Santa Cruz, Calif.). Chloroquine inhibition of Cpg-induced but not LPS-induced NFkB activation was established using J774 cells. The cells were precultured for 2 hr in the presence or absence of chloroquine (20 μg/ml) and then stimulated as above for 1 hr with either EC DNA, Cpg ODN, non-Cpg ODN or LPS (1 μg/ml). Similar chloroquine sensitive Cpg-induced activation of NFkB was seen in a B cell line, WEHI-231 and primary spleen cells. These experiments were performed three times over a range of chloroquine concentrations from 2.5 to 20 μg/ml with similar results.

It was also established that Cpg-stimulated mRNA expression requires endosomal acidification and NFkB activation in B cells and monocytes. J774 cells (2×106 cells/ml) were cultured for 2 hr in the presence or absence of chloroquine (2.5 μg/ml [-5 μM]) or N-tosyl-L-phenylalanine chloromethyl ketone (TPCK, 50 μM), a serine/threonine protease inhibitor that prevents IkB proteolysis and thus blocks NFkB activation. Cells were then stimulated with the addition of E. coli DNA (50 μg/ml), calf thymus DNA (CT, 50 μg/ml), LPS (10 μg/ml), Cpg ODN (1826; 1 μM), or control non-Cpg ODN (1911; 1 μM) for 3 hr. WEHI-231 B cells (5×106 cells/ml) were cultured in the presence or absence of glycotritox (0.1 μg/ml) or bisgluton (0.1 μg/ml) for 2 hr and then stimulated with a Cpg ODN (1826), or control non-Cpg ODN (1911; TCCAGGACITTCTCAGTT; SEQ ID NO:107) at 0.5 μg/ml for 8 hr. In both cases, cells were harvested and RNA was prepared using RNAzol following the manufacturer’s protocol. Multi-probe RNase protection assay was performed as described (A.-K. Yi, P. Hornbeck, D.E. Laffranc and A. M. Krieg, J. Immunol., 157, 4918-4925 (1996)). Cytoplasmic amounts of RNA were loaded into each lane by using ribosomal mRNA as a loading control (L32). These experiments were performed three times with similar results.

The results indicate that leukocytes respond to Cpg DNA through a novel pathway involving the pH-dependent generation of intracellular ROS. The pH dependent step may be the transport or processing of the Cpg DNA, the ROS generation, or some other event. ROS are widely thought to be second messengers in signaling pathways in diverse cell types, but have previously been shown to mediate a stimulatory signal in B cells. Presumably, there is a protein in or near the endosomes that specifically recognizes DNA containing CpG motifs and leads to the generation of reactive oxygen species. To detect any protein in the cell cytoplasm that may specifically bind Cpg DNA, cleftrophoretic mobility shift assays (EMSA) were used with 5’ radioactively labeled oligonucleotides with or without Cpg motifs. A band was found that appears to represent a protein binding specifically to single stranded oligonucleotides that have Cpg motifs, but not to oligonucleotides that lack Cpg motifs or to oligonucleotides in which the Cpg motif has been methylated. This binding activity is blocked if excess of oligonucleotides that contain the NFkB binding site was added. This suggests that an NFkB or related protein is a component of a protein or protein complex that binds the stimulatory Cpg oligonucleotides.

No activation of CREB/ATF proteins was found at time points where NFkB was strongly activated. These data therefore do not provide proof that NFkB proteins actually bind to the Cpg nucleic acids, but rather that the proteins are required in some way for the Cpg activity. It is possible that a CREB/ATF or related protein may interact in some way with NFkB proteins or other proteins thus explaining the remarkable similarity in the binding motifs for CREB proteins and the optimal Cpg motif. It remains possible that the oligos bind to a CREB/ATF or related protein, and that this leads to NFkB activation.

Alternatively, it is very possible that the Cpg nucleic acids may bind to one of the TRAF proteins that bind to the cytoplasmic region of CD40 and mediate NFkB activation when CD40 is cross-linked. Examples of such TRAF proteins include TRAF-2 and TRAF-5.

**Method for Making Immunostimulatory Nucleic Acids**

For use in the instant invention, nucleic acids can be synthesized de novo using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (S. L. Beaucage and M. H. Caruthers, 1981 Tet. Let. 22:1859); nucleoside H-phosphonate method (Garegg et al., 1986) Tet. Let. 27: 4051–4054; Froehler et al., 1986) Nucleos. Res. 14: 5399–5407; Garegg et al., 1986) Tet. Let. 27: 4055–4058; Gaffney et al., 1987) Tet. Let. 29:2619–2622). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market. Alternatively, oligonucleotides can be prepared from existing nucleic acid sequences (e.g. genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in vivo, nucleic acids are preferably relatively resistant to degradation (e.g. via endo- and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphor backbone modifications. A preferred stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made e.g. as described in U.S. Pat. No. 4,469,863; and alkylphosphorothioesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A. (1990) Chem. Rev. 90:544; Goodchild, J. (1990) Bioconjuc-
gate Chem. 1:165). 2'-O-methyl nucleic acids with CpG motifs also cause immune activation, as do ethoxy-modified CpG nucleic acids. In fact, no backbone modifications have been found that completely abolish the CpG effect, although it is greatly reduced by replacing the C with a 5-methyl C.

For administration in vivo, nucleic acids may be associated with a molecule that results in higher affinity binding to target cell (e.g. B-cell, monocytic cell and natural killer (NK) cell) surfaces and/or increased cellular uptake by target cells to form a “nucleic acid delivery complex”. Nucleic acids can be ionically, or covalently associated with appropriate molecules using techniques which are well known in the art. A variety of coupling or crosslinking reagents can be used e.g. protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). Nucleic acids can alternatively be encapsulated in liposomes or virosomes using well-known techniques.

Therapeutic Uses of Immunostimulatory Nucleic Acid Molecules

Based on their immunostimulatory properties, nucleic acid molecules containing at least one unmethylated CpG dinucleotide can be administered to a subject in vitro to treat an “immune system deficiency”. Alternatively, nucleic acid molecules containing at least one unmethylated CpG dinucleotide can be contacted with lymphocytes (e.g. B cells, monocytes and/or NK cells) obtained from a subject having an immune system deficiency ex vivo and activated lymphocytes can then be re-implanted in the subject.

As reported herein, in response to unmethylated CpG containing nucleic acid molecules, an increased number of spleen cells secrete IL-5, IL-12, IFN-γ, IFN-β, GM-CSF, RANTES, and probably others. The increased IL-6 expression was found to occur in B cells, CD4+ T cells and monocytes.

Immunostimulatory nucleic acid molecules can also be administered to a subject in conjunction with a vaccine to boost a subject’s immune system and thereby effect a better response from the vaccine. Preferably the immunostimulatory nucleic acid molecule is administered slightly before or at the same time as the vaccine. A conventional adjuvant may optionally be administered in conjunction with the vaccine, which is minimally comprised of an antigen, as the conventional adjuvant may further improve the vaccination by enhancing antigen absorption.

When the vaccine is a DNA vaccine at least two components determine its efficacy. First, the antigen encoded by the vaccine determines the specificity of the immune response. Second, if the backbone of the plasmid contains CpG motifs, it functions as an adjuvant for the vaccine. Thus, CpG DNA acts as an effective “danger signal” and causes the immune system to respond vigorously to new antigens in the area. This mode of action presumably results primarily from the stimulatory local effects of CpG DNA on dendritic cells and other “professional” antigen presenting cells, as well as from the co-stimulatory effects on B cells.

Immunostimulatory oligonucleotides and unmethylated CpG containing vaccines, which directly activate lymphocytes and co-stimulate an antigen-specific response, are fundamentally different from conventional adjuvants (e.g. aluminum precipitates), which are inert when injected alone and are thought to work through absorbing the antigen and thereby presenting it more effectively to immune cells. Further, conventional adjuvants only work for certain antigens, only induce an antibody (humoral) immune response (Th2), and are very poor at inducing cellular immune responses (Th1). For many pathogens, the humoral response contributes little to protection, and can even be detrimental.

In addition, an immunostimulatory oligonucleotide can be administered prior to, along with or after administration of a chemotherapy or immunotherapy to increase the responsiveness of the malignant cells to subsequent chemotherapy or immunotherapy or to speed the recovery of the bone marrow through induction of restorative cytokines such as GM-CSF. CpG nucleic acids also increase natural killer cell lytic activity and antibody dependent cellular cytotoxicity (ADCC). Induction of NK activity and ADCC may likewise be beneficial in cancer immunotherapy, alone or in conjunction with other treatments.

Another use of the described immunostimulatory nucleic acid molecules is in desensitization therapy for allergies, which are generally caused by IgE antibody generation against harmless allergens. The cytokines that are induced by unmethylated CpG nucleic acids, are predominantly of a class called “Th1” which is most marked by a cellular immune response and is associated with IL-12 and IFN-γ. The other major type of immune response is termed a Th2 immune response, which is associated with more of an antibody immune response and with the production of IL-4, IL-5 and IL-10. In general, it appears that allergic diseases are mediated by Th2 type immune responses and autoimmune diseases by Th1 immune response. Based on the ability of the immunostimulatory nucleic acid molecules to shift the immune response in a subject from a Th2 (which is associated with production of IgE antibodies and allergy) to a Th1 response (which is protective against allergic reactions), an effective dose of an immunostimulatory nucleic acid (or a vector containing a nucleic acid) alone or in conjunction with an allergen can be administered to a subject to treat or prevent an allergy.

CpG nucleic acids containing unmethylated CpG motifs may also have significant therapeutic utility in the treatment of asthma. Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation and mast cell growth. Th1 cytokines, especially IFN-γ and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines.

As described in detail in the following Example 12, oligonucleotides containing an unmethylated CpG motif (i.e., TCCATGACGGTCTTCGAGCAGTT; SEQ ID NO: 10), but not a control oligonucleotide (TCCATGAGCTTCGAGTCT; SEQ ID NO 8) prevented the development of an inflammatory cellular infiltrate and eosinophilia in a murine model of asthma. Furthermore, the suppression of eosinophilic inflammation was associated with a suppression of a Th2 response and induction of a Th1 response.

For use in therapy, an effective amount of an appropriate immunostimulatory nucleic acid molecule alone or formulated as a delivery complex can be administered to a subject by any mode allowing the oligonucleotide to be taken up by the appropriate target cells (e.g. B-cells and monocyte cells). Preferred routes of administration include oral and transdermal (e.g. via a patch). Examples of other routes of administration include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intranasal, intracerebral, intrathecal, etc.). The injection can be in a bolus or a continuous infusion.

A nucleic acid alone or as a nucleic acid delivery complex can be administered in conjunction with a pharmaceutically acceptable carrier. As used herein, the phrase “pharmaceuti-
47

Effectively the 第一 author of a nucleic acid molecule refers to the amount necessary or sufficient to realize a desired biologic effect. For example, an effective amount of a nucleic acid containing at least one unmethylated CpG for treating an immune system deficiency could be that amount necessary to eliminate a tumor, cancer, or bacterial, viral or fungal infection. An effective amount for use as a vaccine adjuvant could be that amount useful for boosting a subject's immune response to a vaccine. An “effective amount” for treating asthma can be that amount useful for redirecting a Th2 type of immune response that is associated with asthma to a Th1 type of response. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular nucleic acid being administered (e.g. the number of unmethylated CpG motifs or their location in the nucleic acid), the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular oligonucleotide without necessitating undue experimentation.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

EXAMPLES

Example 1

Effects of ODNs on B Cell Total RNA Synthesis and Cell Cycle

B cells were purified from spleens obtained from 6-12 wk old specific pathogen free DBA/2 or BXSb mice (bred in the University of Iowa animal care facility; no substantial strain differences were noted) that were depleted of T cells with anti-Thy-1.2 and complement and centrifugation over lymphocyte M (Cedarlane Laboratories, Honey, Ontario, Canada) (“B cells”). B cells contained fewer than 1% CD4+ or CD8+ cells. 8x10^5 B cells were dispensed in triplicate into 96 well microtiter plates in 100 μl RPMI containing 10% FBS (heat inactivated to 65°C for 30 min.), 50 μM 2-mercaptoethanol, 100 μg/ml penicillin, and 100 μg/ml streptomycin, and 2 mM L-glutamate. 20 μM ODN were added at the start of culture for 20 h at 37°C, cells pulsed with 1 μCi of ^3H uridine, and harvested and counted 4 hr later. Ig secreted B cells were enumerated using the ELISA spot assay after culture of whole spleen cells with ODN at 20 μM for 48 hr. Data, reported in Table 1, represent the stimulation index compared to cells cultured without ODN. ^3H thymidine incorporation assays showed similar results, but with some nonspecific inhibition by thymidine released from degraded ODN (Matson. S. and A. M. Krieg (1992) Nonspecific suppression of ^3H-thymidine incorporation by control oligonucleotides. Antisense Research and Development:2:325).

Example 2

Effects of ODN on Production of IgM from B Cells

Single cell suspensions from the spleens of freshly killed mice were treated with anti-Thy1, anti-CD4, and anti-CD8 and complement by the method of Leibson et al., J. Exp. Med. 154:1681 (1981). Resting B cells (~0.2% T cell contamination) were isolated from the 63-70% band of a discontinuous Percoll gradient by the procedure of DeFranco et al, J. Exp. Med. 155:1523 (1982). These were cultured as described above in 30 μM ODN or 20 μg/ml LPS for 48 hr. The number of B cells actively secreting IgM was maximal at this time point, as determined by ELISPOT assay (Kliman, D. M. et al. J. Immunol. 144:506 (1990)). In that assay, B cells were incubated for 6 hrs on anti-Ig coated microtiter plates. The Ig they produced (~99% IgM) was detected using phosphatase-labeled anti-Ig (Southern Bio-technology Associated, Birmingham, Ala.). The antibodies produced by individual B cells were visualized by addition of BCIP (Sigma Chemical Co., St. Louis Mo.) which forms an insoluble blue precipitate in the presence of phosphatase. The dilution of cells producing 20-40 spots/well was used to determine the total number of antibody-secreting B cells/ sample. All assays were performed in triplicate (data reported in Table 1). In some experiments, culture supernatants were assayed for IgM by ELISA, and showed similar increases in response to CpG-ODN.

Example 3

B Cell Stimulation by Bacterial DNA

DBA/2 B cells were cultured with no DNA or 50 μg/ml of a) Micrococcus lysodeikticus; b) NZB/N mouse spleen; and c) NFS/N mouse spleen genomic DNAs for 48 hours, then pulsed with ^3H thymidine for 4 hours prior to cell harvest. Duplicate DNA samples were digested with DNASE I for 30 minutes at 37°C prior to addition to cell cultures. E. coli DNA also induced an 8.8 fold increase in the number of IgM secreting B cells by 48 hours using the ELISA-spot assay.

DBA/2 B cells were cultured with either no additive, 50 μg/ml LPS or the ODN 1; 1μ; 4; or 4μ at 20 μM. Cells were cultured and harvested at 4, 8, 24 and 48 hours. BXSb cells were cultured as in Example 1 with 5, 10, 20, 40 or 80 μM of ODN 1; 1μ; 4; or 4μ. In this experiment, wells with no ODN had 3833 cpm. Each experiment was performed at least three times with similar results. Standard deviations of the triplicate wells were <5%.

Example 4

Effects of ODN on Natural Killer (NK) activity

10x10^6 C57BL/6 spleen cells were cultured in two ml RPMI (supplemented as described for Example 1) with or without 40 μM CpG or non-CpG ODN for forty-eight hours. Cells were washed, and then used as effector cells in a short term 51Cr release assay with YAC-1 and 2C11, two NK sensitive target cell lines (Ballas, Z. K. et al. (1993) J. Immunol. 150:17). Effector cells were added at various concentrations to 10^2 51Cr-labeled target cells in V-bottom microtiter plates in 0.2 ml, and incubated in 5% CO2 for 4 hr. at 37°C. Plates were then centrifuged, and an aliquot of the supernatant counted for radioactivity. Percent specific lysis was determined by calculating the ratio of the 51Cr released in the presence of effector cells minus the 51Cr
released when the target cells are cultured alone, over the total counts released after cell lysis in 2% acetic acid minus the $^{51}$Cr cpm released when the cells are cultured alone.

Example 5

In vivo Studies with Cpg Phosphorothioate ODN

Mice were weighed and injected IP with 0.25 ml of sterile PBS or the indicated phosphorothioate ODN dissolved in PBS. Twenty four hours later, spleen cells were harvested, washed, and stained for flow cytometry using phycoerythrin conjugated 6B2 to gate on B cells in conjunction with biotin conjugated anti-Ly-6A/E or anti-4E (Pharmingen, San Diego, Calif.) or anti-Bl-1 (Hardy, R. R. et al., J. Exp. Med. 159:1169 (1984)). Two mice were studied for each condition and analyzed individually.

Example 6

Titration of Phosphorothioate ODN for B Cell Stimulation

B cells were cultured with phosphorothioate ODN with the sequence of control ODN 1a or the Cpg ODN 1d and 3db and then either pulsed after 20 hr with $^3$H uridine or after 24 hr with $^3$H thymidine before harvesting and determining cpm.

Example 7

Rescue of B Cells From Apoptosis

WEHI-231 cells (5x10$^4$/well) were cultured for 1 hr. at 37 C. in the presence or absence of LPS or the control ODN 1a or the Cpg ODN 1d and 3db before addition of anti-IgM (1 $\mu$g/ml). Cells were cultured for a further 20 hr. before a 4 hr. pulse with 2 $\mu$Ci/well $^3$H thymidine. In this experiment, cells with no ODN or anti-IgM gave 90.4x10$^3$ cpm of $^3$H thymidine incorporation by addition of anti-IgM. The phosphorothioate ODN shown in Table 1 gave similar protection, though with some nonspecific suppression due to ODN degradation. Each experiment was repeated at least 3 times with similar results.

Example 8

In vivo Induction of Murine IL-6

DBA/2 female mice (2 mos. old) were injected IP with 500 g Cpg or control phosphorothioate ODN. At various time points after injection, the mice were bled. Two mice were studied for each time point. IL-6 was measured by ELISA, and IL-6 concentration was calculated by comparison to a standard curve generated using recombinant IL-6. The sensitivity of the assay was 10 pg/ml. Levels were undetectable after 8 hr.

Example 9

Systemic Induction of Murine IL-6 Transcription

Mice and cell lines. DBA/2, BALB/c, and C3H/HeJ mice at 5–10 wk of age were used as a source of lymphocytes. All mice were obtained from The Jackson Laboratory (Bar Harbor, Me.), and bred and maintained under specific pathogen-free conditions in the University of Iowa Animal Care Unit. The mouse B cell line CH12.LX was kindly provided by Dr. G. Bishop (University of Iowa, Iowa City).

Cell preparation. Mice were killed by cervical dislocation. Single cell suspensions were prepared aseptically from the spleens from mice. T cell depleted mouse splenocytes were prepared by using anti-Thy-1.2 and complement and centrifugation over lymphocyte M (Cedarlane Laboratories, Hombay, Ontario, Canada) as described (Krieg, A. M. et al., (1989) A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J. Immunol. 143:2448).

ODN and DNA. Phosphodiester oligonucleotides (O-ODN) and the backbone modified phosphorothioate oligonucleotides (S-ODN) were obtained from the DNA Core facility at the University of Iowa or from Operon Technologies (Alameda, Calif.). E. coli DNA (Strain B) and calf thymus DNA were purchased from Sigma (St. Louis, Mo.). All DNA and ODN were purified by extraction with phenol/chloroform/isooamyl alcohol (25:24:1) and/or ethanol precipitation. E. coli and calf thymus DNA were single stranded prior to use by boiling for 10 min. followed by cooling on ice for 5 min. For some experiments, E. coli and calf thymus DNA were digested with DNase I (2U/g of DNA) at 37°C for 2 hr in 1×SSC with 5 mM MgCl2. To methylate the cytosine in Cpg dimucleotides in E. coli DNA, E. coli DNA was treated with Cpg methylase (M. SssI; 2 U/µg of DNA) in NEBuffer 2 supplemented with 160 mM S-adenosyl methionine and incubated overnight at 37°C. Methylated DNA was purified as above. Efficiency of methylation was confirmed by Hpa II digestion followed by analysis by gel electrophoresis. All enzymes were purchased from New England Biolabs (Beverly, Mass.). LPS level in ODN was less than 12.5 ng/mg and E. coli and calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA by Limulus assay.

Cell Culture. All cells were cultured at 37°C in a 5% CO2 incubator maintained in RPMI-1640 supplemented with 10% fetal calf serum (FCS), 1.5 mM L-glutamine, 50 µg/ml). Cpg or non-Cpg phosphodiester ODN (O-ODN) (20 µM), phosphorothioate ODN (S-ODN) (0.5 µM), or E. coli or calf thymus DNA (50 µg/ml) at 37°C for 24 hr. (for IL-6 production) or 5 days (for IgM production). Concentrations of stimulants were chosen based on preliminary studies with titrations. In some cases, cells were treated with Cpg O-ODN along with various concentrations (1–10 µg/ml) of neutralizing rat IgG1 antibody against murine IL-6 (hybrydoma MP5-20F3) or control rat IgG1 mAb to E. coli B-galactosidase (hybrydoma GL113; ATCC, Rockville, Md.) (20) for 5 days. At the end of incubation, culture supernatant fractions were analyzed by ELISA as below.

In vivo induction of IL-6 and IgM. BALB/c mice were injected intravenously (iv) with PBS, calf thymus DNA (200 µg/100 µl PBS/mouse), E. coli DNA (200 µg/100 µl PBS/mouse), or Cpg or non-Cpg S-ODN (200 µg/100 µl PBS/mouse). Mice (two/group) were bled by retroorbital puncture and sacrificed by cervical dislocation at various time points. Livers, spleen, thymus, and bone marrow were removed and RNA was prepared from those organs using RNeazol B (Tel-Test, Friendswood, Tex.) according to the manufacturer’s protocol.

ELISA. Flat-bottomed Immun 1 plates (Dynatech Laboratories, Inc., Chantilly, Va.) were coated with 100 µl/well of anti-mouse IL-6 mAb (MPS-20F3) (2 µg/ml) or anti-mouse IgM µ-chain specific (5 µg/ml; Sigma, St. Louis, Mo.) in carbonate-bicarbonate, pH 9.6 buffer (15 mM Na$_2$CO$_3$, 35 mM NaHCO$_3$) overnight at 4°C. The plates were then washed with TBS (0.5 mM MgCl$_2$0H$_2$, 2.68 mM KCl, 1.47 mM KH$_2$PO$_4$, 0.14 M NaCl, 6.6 mM, K$_2$HPO$_4$, 0.5% Tween 20) and blocked with 10% FCS in TBS for 2 hr at room temperature and then washed again. Culture supernatants, mouse sera, recombinant mouse IL-6
Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs

ODN were synthesized on an Applied Biosystems Inc. (Foster City, Calif.) model 380A, 380B, or 394 DNA synthesizer using standard procedures (Beacage and Caruthers (1981) Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolyolnucleotide synthesis. Tetrahedron Letters 22, 1859–1862). Phosphodiester ODN were synthesized using standard beta-cyanethyl phosphoramidite chemistry. Phosphorothioate linkages were introduced by oxidizing the phosphate linkage with elemental sulfur instead of the standard iodine oxidation. The four common nucleoside phosphoramidites were purchased from Applied Biosystems. All phosphodiester and thioate containing ODN were depurinated by treatment with concentrated ammonia at 55°C for 12 hours. The ODN were purified by gel exclusion chromatography and lyophilized to dryness prior to use. Phosphorothioate linkages were introduced by using deoxynucleoside S-(β-D-arabinofuranosyl)pyrroli dinolipidophosphoramidites (Wiesler, W. T. et al., (1993) In Methods in Molecular Biology: Protocols for Oligonucleotides and Analytes—Synthesis and Properties, Agrawal, S. (ed.), Humana Press, 191–206.). Dithioate containing ODN were depurinated and treated with concentrated ammonia at 55°C for 12 hours followed by reverse phase HPLC purification.

In order to synthesize oligomers containing methylphosphonothioates or methylphosphonates as well as phosphodiesters at any desired internucleotide linkage, two different synthetic cycles were used. The major synthetic differences in the two cycles are the coupling reagent where dialkylaminomethylphosphonates are used and the oxidation reagents in the case of methylphosphonothioates. In order to synthesize either derivative, the condensation time has been increased for the dialkylaminomethylphosphonates due to the slower kinetics, of coupling (Jager and Engels, (1984) Synthesis of deoxynucleoside methylphosphonates via a phosphoramidite approach. Tetrahedron Letters 24, 1347–1440). After the coupling step has been completed, the methylphosphodiester is treated with the sulfurizing reagent (5% elemental sulfur, 100 millimolar N,N-dimethylaminopyridine in carbon disulfide/pyridine/triethylamine), four consecutive times for 450 seconds each to produce methylphosphonothioates. To produce methylphosphonate linkages, the methylphosphodiester is treated with standard oxidizing reagent (0.1 M iodine in tetrahydrofuran/2,6-lutidine/water).

The silica gel bound oligomer was treated with distilled pyridine/concentrated ammonia, 1:1, (v/v) for four days at 4 degrees centigrade. The supernatant was dried in vacuo, dissolved in water and chromatographed on a G50/50 Sephadex column.

As used herein, O-ODN refers to ODN which are phosphodiester; S-ODN are completely phosphorothioate modified; S-O-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorothioate modified; S2-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are phosphorothioate modified; and MP-ODN are chimeric ODN in which the central linkages are phosphodiester, but the two 5′ and five 3′ linkages are methylphosphonate modified. The ODN sequences studied (with CpG dinucleotides indicated by underlining) include:

(PharMingen, San Diego, Calif) or purified mouse IgM (Calbiochem, San Diego, Calif.) were appropriately diluted in 10% FCS and incubated in triplicate wells for 6 h at room temperature. The plates were washed and 100 μl/well of biotinylated rat anti-mouse IL-6 monoclonal antibodies (MP5-32C11, PharMingen, San Diego, Calif.) (1 μg/ml in 10% FCS) or biotinylated anti-mouse IgG (Sigma, St. Louis, Mo.) were added and incubated for 45 min. at room temperature following washes with TBS. Horseradish peroxidase (HRP) conjugated avidin (Bio-rad Laboratories, Hercules, Calif.) at 1:4000 dilution in 10% FCS (100 μl/well) was added and incubated at room temperature for 30 min. The plates were washed and developed with o-phenylenediamine dihydrochloride (OPD) (Sigma, St. Louis, Mo) 0.05 M phosphate-citrate buffer, pH 5.4, for 30 min. The reaction was stopped with 0.67 N H2SO4 and the plates were read on a microplate reader (Cambridge Technology, Inc., Watertown, Mass.) at 490–600 nm. The results are shown in FIGS. 1 and 2.

RT-PCR. A sense primer, an antisense primer, and an internal oligonucleotide probe for IL-6 were synthesized using published sequences (Montgomery, R. A. and M. S. Dallman (1991), Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction (J. Immunol.) 147:554). cDNA synthesis and IL-6 PCR was done essentially as described by Montgomery and Dallman (Montgomery, R. A. and M. S. Dallman (1991), Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction (J. Immunol.) 147:554) using RT-PCR reagents from Perkin-Elmer Corp. (Hayward, Calif.). Samples were analyzed after 30 cycles of amplification by gel electrophoresis followed by un blot analysis (Stoye, J. P. et al., (1991) DNA hybridization in dried gels with fragmented probes: an improvement over blotting techniques, Techniques 3:123). Briefly, the gel was hybridized at room temperature for 30 min. in denaturation buffer (0.05 M NaOH, 1.5M NaCl) followed by incubation for 30 min. in renaturation buffer (1.5 M NaCl, 1 M Tris, pH 8) and a 30 min. wash in double distilled water. The gel was (tried and prehybridized at 47°C for 2 h, hybridization buffer (5xSSPE, 0.1% SDS) containing 10 μg/ml denatured salmon sperm DNA. The gel was washed with 2x105 cpm/ml g-32P ATP end-labeled internal oligonucleotide probe for IL-6 (5’CATTTTACACAGTTTCCA3’ SEQ ID No. 109) overnight at 47°C, washed 4 times (2xSSC, 0.2% SDS) at room temperature and autoradiographed. The results are shown in FIG. 3.

Cell Proliferation assay. DBA2 mice spleen B cells (5x106 cells/100 μl/well) were treated with media, CpG or non-CpG S-ODN (0.5 μM) or O-ODN (20 μM) for 24 h at 37°C. Cells were pulsed for the last 4 h with either [3H] Thymidine or [3H] Uridine (1 μCi/well). Amounts of [3H] incorporated were measured using Liquid Scintillation Analyzer (Packard Instrument Co., Downers Grove, IL).
3D (5′ GAGAACCTTGGGACCTTCAGT), (SEQ. ID. NO. 20);
3M (5′ TCCATGTGCTTCTGTAGFTGCT), (SEQ. ID. NO. 28);
5 (5′ GGCTTATATCTCGACTGGCC), (SEQ. ID. NO. 110); and
6 (5′ CCTACTCTAGTATGCGGCCGACGT), (SEQ. ID. NO. 111).

These sequences are representative of literally hundreds of CpG and non-CpG ODN that have been tested in the course of these studies.

Mice, DBA/2, or BXSB mice obtained from The Jackson Laboratory (Bar Harbor, Me.), and maintained under specific pathogen-free conditions were used as a source of lymphocytes at 5–10 wk of age with essentially identical results.

Cell proliferation assay. For cell proliferation assays, mouse spleen cells (5 × 10⁶ cells/100 μl/well) were cultured at 37°C in a 5% CO₂ humidified incubator in RPMI-1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (heated to 65°C for experiments with O-ODN, or 56°C for experiments using only modified ODN), 1.5 μM L-glutamine, 50 μM 2-mercaptoethanol, 100 μM penicillin and 100 μg/ml streptomycin for 24 hr or 48 hr as indicated. 1 μCi of ³H uridine or thymidine (as indicated) was added to each well, and the cells harvested after an additional 4 hours of culture. Filters were counted by scintillation counting. Standard deviations of the triplicate wells were <5%.

The results are presented in FIGS. 6–8.

Example 11
Induction of NK Activity

Phosphodiester ODN were purchased from Operon Technologies (Alameda, Calif.). Phosphorothioate ODN were purchased from the DNA core facility, University of Iowa, or from The Midland Certified Reagent Company (Midland, Tex.). E. coli (strain B) DNA and calf thymus DNA were purchased from Sigma (St. Louis, Mo.). All DNA and ODN were purified by extraction with phenol/chloroform/isoamyl alcohol (25:24:1) and/or ethanol precipitation. The LPS level in ODN was less than 12.5 ng/mg and E. coli and calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA by Limulus assay.

Virus-free, 4–6 week old, DBA/2, C57BL/6 (B6) and congenitally athymic BALB/C mice were obtained on contract through the Veterans Affairs from the National Cancer Institute (Bethesda, Md.). C57BL/6 SCID mice were bred in the SPF barrier facility at the University of Iowa Animal Care Unit.


5Cr-release assay against K562 (human) or YAC-1 (mouse) target cells as previously described. For calculation of lytic

units (LU), 1 LU was defined as the number of cells needed to effect 30% specific lysis. Where indicated, neutralizing antibodies against IFN-γ (Lee Molecular, San Diego, Calif.) or IL-12 (C15.1, C15.6, C17.8, and C17.15; provided by Dr. Giorgio Trinchieri, The Wistar Institute, Philadelphia, Pa.) or their isotype controls were added at the initiation of cultures to a concentration of 10 μg/ml. For anti-IL-12 addition, 10 μg each of the 4 MAB (or isotype controls) were added simultaneously. Recombinant human IL-2 was used at a concentration of 100 U/ml.

Example 12
Prevention of the Development of an Inflammatory Cellular Infiltrate and Eosinophilia in a Murine Model of Asthma

6–8 week old C56BL/6 mice (from The Jackson Laboratory, Bar Harbor, Me.) were immunized with 5,000 Schistosoma mansoni eggs by intraperitoneal (i.p.) injection on days 0 and 7. Schistosoma mansoni eggs contain an antigen (Schistosoma mansoni egg antigen (SEA)) that induces a Th2 immune response (e.g. production of IgE antibody). IgE antibody production is known to be an important cause of asthma.

The immunized mice were then treated with oligonucleotides (30 μg in 200 μl saline by i.p injection), which either contained an unmethylated CpG motif (i.e., TCCAGAGCAGTCGACGT; SEQ ID NO.10) or did not (i.e., control, TCCATGAGCTCGTTCGAGTCT; SEQ ID NO.8). Soluble SEA (10 μg in 25 μl of saline) was administered by intranasal instillation on days 14 and 21. Saline was used as a control.

Mice were sacrificed at various times after airway challenge. Whole lung lavage was performed to harvest airway and alveolar inflammatory cells. Cytokine levels were measured from lavage fluid by ELISA. RNA was isolated from whole lung for Northern analysis and RT-PCR studies using CsCl gradients. Lungs were inflated and perfused with 4% paraformaldehyde for histologic examination.

FIG. 9 shows that when the mice are initially injected with the eggs i.p., and then inhale the egg antigen (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given a nucleic acid containing an unmethylated CpG motif along with the eggs, the inflammatory cells in the lung are not increased by subsequent inhalation of the egg antigen (open triangles).

FIG. 10 shows that the same results are obtained when only eosinophils present in the lung lavage are measured. Eosinophils are the type of inflammatory cell most closely associated with asthma.

FIG. 11 shows that when the mice are treated with a control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA. Thus, when mice inhale the eggs on days 14 or 21, they develop an acute inflammatory response in the lungs. However, giving a CpG oligo along with the eggs at the time of initial antigen exposure on days 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.

FIG. 12 shows that very low doses of oligonucleotide (<10 μg) can give this protection.

FIG. 13 shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.

FIG. 14 shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect
the cytokine response of the lung to production of IL-12, indicating a Th1 type of immune response. FIG. 15 shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN-γ, indicating a Th1 type of immune response.

Example 13

CpG Oligonucleotides Induce Human PBMC to Secrete Cytokines

Human PBMC were prepared from whole blood by standard centrifugation over ficoll hypaque. Cells (5×10⁷/ml) were cultured in 10% autologous serum in 96 well microtiter plates with CpG or control oligodeoxynucleotides (24 μg/ml for phosphodiester oligonucleotides; 6 μM for nuclease resistant phosphorothioate oligonucleotides) for 4 hr in the case of TNF-α or 24 hr. for the other cytokines before supernatant harvest and assay, measured by ELISA using Quantikine kits or reagents from R&D Systems (pg/ml) or cytokine ELISA kits from Biosource (for IL-12 assay). Assays were performed as per the manufacturer’s instructions. Data are presented in Table 6 as the level of cytokine above that in wells with no added oligodeoxynucleotide.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 111

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
ANGGAAAGCT CACGCTTC

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
ANGACCTAC GCGTGCCT

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
TCATAAGCT TCTGAGCT

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs

...
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCTGATGTT ACGUT 15

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GAGAAACGTC ACCTGGCAT 19

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCAYGACUT GAQCT 15

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TCCAGACGT TCCTGAGCTC 20

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TCCATGACGT TCCTGAGCTC 20

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TCCAAGACT TCCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TCCAAGACT TCCTGACGT

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

TCCAAGACT TCCTGASTGC T

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GGGTCGAACG TGAGGCGGG

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 7...7
(D) OTHER INFORMATION: where N at position 7 is 5 methyl cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GCTAGANOTT AGCOT

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 7...7
(D) OTHER INFORMATION: N at position 7 is 5 methyl cytosine
(A) NAME/KEY: misc_feature
(B) LOCATION: 13...13
(D) OTHER INFORMATION: N at position 13 is 5 methyl cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GCTAGANOT AGNOT

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRAND: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ATGCACCTGC GACCTGC

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRAND: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3...3
(D) OTHER INFORMATION: where N at position 3 is 5 methyl cytosine
(A) NAME/KEY: misc_feature
(B) LOCATION: 10...10
(D) OTHER INFORMATION: where N at position 10 is 5 methyl cytosine
(A) NAME/KEY: misc_feature
(B) LOCATION: 14...14
(D) OTHER INFORMATION: where N at position 14 is 5 methyl cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

ATNGACTCNGAGNOTCTC

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRAND: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3...3
(D) OTHER INFORMATION: where N at position 3 is 5 methyl cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 18..18
(D) OTHER INFORMATION: where N at position 18 is 5 methyl cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

ATGACTCTC GACCCCTC

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATGGAAGTCC CAACCTTC

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GAGAACGCTG GACCCCTCAT

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GAGAACGCTG GACCTCCCAT

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GAGAAGCTG GACCTCCAT

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GAGCAAGCTG GACCTCCAT

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
   (A) NAME/KEY: misc_feature
   (B) LOCATION: 6..6
   (D) OTHER INFORMATION: where N at position 6 is 5 methyl
   cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

GAGAAGCTG GACCTCCAT

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
   (A) NAME/KEY: misc_feature
   (B) LOCATION: 14..14
   (D) OTHER INFORMATION: where N at position 14 is 5 methyl
   cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GAGAAGCTG GACCTCCAT

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GAGAAGCTG GACCTCCAT

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
GAGAAGCTCCACACACTGT

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
TCCATGTCGTCCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
TCCATGTCGTCCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
   (A) NAME/KEY: misc_feature
   (B) LOCATION: 8...8
   (D) OTHER INFORMATION: where N at position 8 is 5 methyl cytosine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
TCCATGNGGTCCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
   (A) NAME/KEY: misc_feature
   (B) LOCATION: 12...12
   (D) OTHER INFORMATION: where N at position 12 is 5 methyl cytosine
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:
TCCATGTCG TCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
TCCATGTCG TCTCCTGAT

(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:
TCCATGTCG TCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
TCCATGTCG TCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
TCCATGTCG TCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:
TCCATGTCG TCTGATGCT

20
(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

TCCATAGC GCCTGATCCT

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

TCCATAGC GCCTGATCCT

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

TCCATAGC GCCTGATCCT

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

TCCATAGC GCCTGATCCT

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GGGCTCAAG TCAGCAAGG

(2) INFORMATION FOR SEQ ID NO: 42:
(i) **SEQUENCE CHARACTERISTICS:**
(A) **LENGTH:** 15 base pairs  
(B) **TYPE:** nucleic acid  
(C) **STRANDEDNESS:** single  
(D) **TOPOLOGY:** linear

(ii) **MOLECULE TYPE:** cDNA

(xi) **SEQUENCE DESCRIPTION:** SEQ ID NO: 42:

```
GCTAGACCTT AGTGT
```

(2) **INFORMATION FOR SEQ ID NO: 43:

(i) **SEQUENCE CHARACTERISTICS:**
(A) **LENGTH:** 15 base pairs  
(B) **TYPE:** nucleic acid  
(C) **STRANDEDNESS:** single  
(D) **TOPOLOGY:** linear

(ii) **MOLECULE TYPE:** cDNA

(ix) **FEATURE:**
(A) **NAME/KEY:** misc_feature  
(B) **LOCATION:** 8...8  
(D) **OTHER INFORMATION:** where N at position 8 is 5 methyl cytosine

(xi) **SEQUENCE DESCRIPTION:** SEQ ID NO: 43:

```
GCTAGACCTT AGTGT
```

(2) **INFORMATION FOR SEQ ID NO: 44:

(i) **SEQUENCE CHARACTERISTICS:**
(A) **LENGTH:** 20 base pairs  
(B) **TYPE:** nucleic acid  
(C) **STRANDEDNESS:** single  
(D) **TOPOLOGY:** linear

(ii) **MOLECULE TYPE:** cDNA

(ix) **FEATURE:**
(A) **NAME/KEY:** misc_feature  
(B) **LOCATION:** 8...8  
(D) **OTHER INFORMATION:** where N at position 8 is 5 methyl cytosine

(xi) **SEQUENCE DESCRIPTION:** SEQ ID NO: 44:

```
TCCATGATG TCTTGAAGCT
```

(2) **INFORMATION FOR SEQ ID NO: 45:

(i) **SEQUENCE CHARACTERISTICS:**
(A) **LENGTH:** 18 base pairs  
(B) **TYPE:** nucleic acid  
(C) **STRANDEDNESS:** single  
(D) **TOPOLOGY:** linear

(ii) **MOLECULE TYPE:** cDNA

(xi) **SEQUENCE DESCRIPTION:** SEQ ID NO: 45:

```
TCTCCAGGCT TGCCCAT
```

(2) **INFORMATION FOR SEQ ID NO: 46:

(i) **SEQUENCE CHARACTERISTICS:**
(A) **LENGTH:** 24 base pairs  
(B) **TYPE:** nucleic acid  
(C) **STRANDEDNESS:** single  
(D) **TOPOLOGY:** linear

(ii) **MOLECULE TYPE:** cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:
TCGTCGTTT GTTCGTTT CT

(2) INFORMATION FOR SEQ ID NO: 47:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 47:
TCGTCGTTT GTTCGTTT CTT

(2) INFORMATION FOR SEQ ID NO: 48:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 21 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 48:
TCGTCGTTT GTTCGTTTT CTT T

(2) INFORMATION FOR SEQ ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 22 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 49:
TCGTCGTTT GTTCGTTTGC TT

(2) INFORMATION FOR SEQ ID NO: 50:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 19 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 50:
TCGTCGTT CTTGTTTTT

(2) INFORMATION FOR SEQ ID NO: 51:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 14 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 51:
TCGTCGTT CTT
(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

TCCTTCGCT CCTTCGCTTT

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

TCCTTCGCT TTTCGCTTT

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

TCCTTCGCT CTGccCTTCT T

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

TCCTTCGCT CTGccCTTCT T

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

GCCTTCGCT GCCTTCGCT T

(2) INFORMATION FOR SEQ ID NO: 57:

(continued)
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:16 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

GTCOTT

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

GTCGCT

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:18 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

ACCATGGACG ATCTGTTTCC CCCC

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

TACCCTGTC GACGCTCT

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

ACCATGGACG AACTGTTTCC CCCC

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

ACCAUGAAG AGCTTGTCCC CCTC

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

ACCAUGAAG AGCTTGTCCC CCTC

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

ACCAUGAAG TGCTTGTCCC CCTC

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

ACCAUGAAG GTCTTGTCCC CCTC

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

ACCAUGAAGTTCTTGTCCC CCTC

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLGY: linear

(ii) MOLECULE TYPE: cDNA
(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 68:
CACCTGAGGC GCCAT

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 69:
CCTUCGTAGC TGGAG

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 70:
TGACGCTTGCC

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 71:
ATGACGTCC TGACCTT

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 72:
TCTCCAGGCG GCCGCAT

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 73:
TCTCCAGGCG GCCGCAT
(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

TCCAGTCGT TCTTGCGT

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:21 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

TCCATAGGT TCTTGCGT

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:21 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

TCGTCGCTG TCCCGCCCTC C

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:19 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

TCCTGACGT CCTGACGT

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:19 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

TCCTGACGT CCTGACGT

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

TCCACGCCT TTTCGCCTT

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

TCCACGCCT CTCTCAGCTT

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

TCCACGCCT CTGGTTCTTT

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

TCCACGCCT GCGTTGCCTT

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

TCCACGCCT TTTCGCAGCTT

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:
GCGGCGGCG GCGGCGGCCC

(2) INFORMATION FOR SEQ ID NO: 84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:
TCTCCTTCTG TCTCCTTCTG TCTT

(2) INFORMATION FOR SEQ ID NO: 85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:
TCTCCTTCTG TT

(2) INFORMATION FOR SEQ ID NO: 86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:
TCCACGACTT TCGACOTT

(2) INFORMATION FOR SEQ ID NO: 87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:
TCCATGACGA TCTGATGCT

(2) INFORMATION FOR SEQ ID NO: 88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:
(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi)cession DESCRIPTION: SEQ ID NO: 89:

TCCATGACGT CCTGAGATCT

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi)cession DESCRIPTION: SEQ ID NO: 90:

GGGOTCAACG TGGAGGCGG

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:15 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi)cession DESCRIPTION: SEQ ID NO: 91:

GCTAGACGT AGGCT

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:15 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi)cession DESCRIPTION: SEQ ID NO: 92:

GCTAGACGT GAGCT

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi)cession DESCRIPTION: SEQ ID NO: 93:

TCCATGACGT TCTGCTGAT
(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

TCAAGCCTT

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

TCAAGCCTT

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

TCAAGCCTT

(2) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

TCATCGAT

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

TCTTCGAA

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

CCAACGTT

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:8 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

TCAACGTC

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

TCCAGGCTG TCCTGATCT

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

TCCAGGCTG TCCTGATCT

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

TCGATAG TCCTGATCT

(2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

TCCTAGATCC CTTCCAGTCT

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

TCCTAGATTC CTTCCAGTCT

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

TCCTAGATTC CTTCCAGTCT

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

TCCTAGATTC CTTCCAGTCT

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

TCCTAGATTC CTTCCAGTCT

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:
We claim:
1. A method for inducing IL-6 in a subject comprising administering to the subject an effective amount to induce IL-6 in the subject of an immunostimulatory nucleic acid, having a sequence comprising:

5'X₁₆C⁻G⁻X₆₃

wherein C is unmethylated, wherein X₁, X₂, X₃, and X₄ are nucleotides, and wherein the 5' X₁₆C⁻G⁻X₃ sequence is a non-palindromic sequence.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the nucleic acid has 8 to 100 nucleotides.

4. The method of claim 1, wherein the nucleic acid backbone includes a phosphate backbone modification on the 5' inter-nucleotide linkages.

5. The method of claim 1, wherein the nucleic acid backbone includes a phosphate backbone modification on the 3' inter-nucleotide linkages.

6. The method of claim 1, wherein the nucleic acid includes a phosphate backbone modification.


8. The method of claim 1, wherein X₁₋X₂ are GpA and X₃₋X₇ are TpT.

9. The method of claim 1, wherein X₁ and X₂ are purines and X₃₋X₇ are pyrimidines.

10. The method of claim 1, wherein X₁₋X₂ are GpA and X₃₋X₇ are pyrimidines.

11. The method of claim 1, wherein the immunostimulatory nucleic acid, has a sequence comprising:

5'X₁₆C⁻G⁻X₆₃

wherein X₁, X₂, X₃, and X₄ are nucleotides and N is a nucleic acid sequence comprised of from about 2-25 nucleotides.

12. The method of claim 1, wherein the immunostimulatory nucleic acid sequence is selected from the group consisting of sequences comprising the following nucleotides: TCCATGTCGGTCTCGATGCT (SEQ ID NO:37); TCCATGACGTGTCTCGATGCT (SEQ ID NO:41); TCCATGACGTGTCTCGATGCT (SEQ ID NO:47); and TCCATGACGTGTCTCGATGCT (SEQ ID NO:53).

13. The method of claim 1, wherein the immunostimulatory nucleic acid sequence comprises the following nucleotides: TCCATGTCGGTCTCGATGCT (SEQ ID NO:37); TCCATGACGTGTCTCGATGCT (SEQ ID NO:41); TCCATGACGTGTCTCGATGCT (SEQ ID NO:47); and TCCATGACGTGTCTCGATGCT (SEQ ID NO:53).

14. A method of stimulating natural killer cell lytic activity comprising exposing a natural killer cell to an immunostimulatory nucleic acid to stimulate natural killer cell lytic activity, the immunostimulatory nucleic acid having a sequence comprising:

5'X₁₆C⁻G⁻X₆₃

wherein C is unmethylated, wherein X₁, X₂, and X₃ are nucleotides, and wherein the 5'X₁₆C⁻G⁻X₃ sequence is a non-palindromic sequence.

15. The method of claim 14, wherein the nucleic acid has 8 to 100 nucleotides.

16. The method of claim 14, wherein the nucleic acid backbone includes a phosphate backbone modification on the 5' inter-nucleotide linkages.

17. The method of claim 14, wherein the nucleic acid backbone includes a phosphate backbone modification on the 3' inter-nucleotide linkages.

18. The method of claim 14, wherein the nucleic acid includes a phosphate backbone modification.

20. The method of claim 14, wherein $X_1, X_2$ are GpA and $X_1, X_2$ are TpT.

21. The method of claim 14, wherein $X_1$ and $X_2$ are purines and $X_2$ and $X_4$ are pyrimidines.

22. The method of claim 14, wherein $X_1, X_2$ are GpA, and $X_2, X_4$ are pyrimidines.

23. The method of claim 14, wherein the immunostimulatory nucleic acid is 8 to 40 nucleotides in length.

24. The method of claim 15, wherein the immunostimulatory nucleic acid, has a sequence comprising:

$$5'NX_1,CGX_2X_3X_43'$$

wherein $X_1$, $X_2$, $X_3$, and $X_4$ are nucleotides and N is a nucleic acid sequence composed of from about 2-25 nucleotides.

25. The method of claim 14, wherein the immunostimulatory nucleic acid sequence is selected from the group consisting of sequences comprising the following nucleotides: TCGTCTGTTGCTGTTGCTGTT (SEQ ID NO:47); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:85); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:89); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:7); TCGTCTGTTGCTGTTGCTGTT (SEQ ID NO:49); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:52); TCGTCTGTTGCTGTTGCTGTT (SEQ ID NO:48); TCGTCTGTTGCTGTTGCTGTT (SEQ ID NO:50); and TCGTCTGTTGCTGCTGCTGCT (SEQ ID NO:51).

26. A method for inducing interferon-gamma in a subject to treat an immune system deficiency, comprising:

administering to a subject having an immune system deficiency an effective amount to induce interferon-gamma production in the subject of an immunostimulatory nucleic acid, having a sequence comprising:

$$5'NX_1,CGX_2X_3X_43'$$

wherein C is unmethylated, wherein $X_1, X_2, X_3$, and $X_4$ are nucleotides, and wherein the sequence of the formula $X_1,CGX_2X_3X_4$ is not palindromic.

27. The method of claim 26, wherein the nucleic acid has 8 to 100 nucleotides.

28. The method of claim 26, wherein the nucleic acid backbone includes a phosphate backbone modification on the 5' inter-nucleotide linkages.

29. The method of claim 26, wherein the nucleic acid backbone includes a phosphate backbone modification on the 3' inter-nucleotide linkages.


31. The method of claim 26, wherein $X_1, X_2$ are GpA and $X_1, X_2$ are TpT.

32. The method of claim 26, wherein $X_1$ and $X_2$ are purines and $X_2$ and $X_4$ are pyrimidines.

34. The method of claim 26, wherein $X_1, X_2$ are GpA and $X_2, X_4$ are pyrimidines.

35. The method of claim 26, wherein the immunostimulatory nucleic acid is 8 to 40 nucleotides in length.

36. The method of claim 26, wherein the immunostimulatory nucleic acid, has a sequence comprising:

$$5'NX_1,CGX_2X_3X_43'$$

wherein $X_1$, $X_2$, $X_3$, and $X_4$ are nucleotides and N is a nucleic acid sequence composed of from about 2-25 nucleotides.

37. A method for inducing IL-12 in a subject comprising:

administering to the subject an effective amount to induce IL-12 in the subject, of an immunostimulatory nucleic acid having a sequence comprising:

$$5'NX_1,CGX_2X_3X_43'$$

wherein C is unmethylated, wherein $X_1, X_2, X_3$, and $X_4$ are nucleotides, and wherein the sequence of the formula $X_1,CGX_2X_3X_4$ is not palindromic.

38. The method of claim 37, wherein the subject is human.

39. The method of claim 37, wherein the immunostimulatory nucleic acid sequence is selected from the group consisting of sequences comprising the following nucleotides: TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:37); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:87); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:34); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:28); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:88); TCCATGACGCTCTGCTGCTGCT (SEQ ID NO:38); and TCGTCTGTTGCTGTTGCTGTT (SEQ ID NO:46).

40. The method of claim 37, wherein the nucleic acid has 8 to 100 nucleotides.

41. The method of claim 37, wherein the nucleic acid backbone includes a phosphate backbone modification on the 5' inter-nucleotide linkages.

42. The method of claim 37, wherein the nucleic acid backbone includes a phosphate backbone modification on the 3' inter-nucleotide linkages.

43. The method of claim 37, wherein the nucleic acid includes a phosphate backbone modification.


45. The method of claim 37, wherein $X_1, X_2$ are GpA and $X_1, X_2$ are TpT.

46. The method of claim 37, wherein $X_1$ and $X_2$ are purines and $X_2$ and $X_4$ are pyrimidines.

47. The method of claim 37, wherein $X_1, X_2$ are GpA and $X_2, X_4$ are pyrimidines.

48. The method of claim 37, wherein the immunostimulatory nucleic acid is 8 to 40 nucleotides in length.

49. The method of claim 37, wherein the immunostimulatory nucleic acid, has a sequence comprising:

$$5'NX_1,CGX_2X_3X_43'$$

wherein $X_1$, $X_2$, $X_3$, and $X_4$ are nucleotides and N is a nucleic acid sequence composed of from about 2-25 nucleotides.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.
Item [75], Inventors: **Arthur M. Krieg**, Iowa City, IA (US); **Dennis Klinman**, Potomac, MD (US); and **Alfred D. Steinberg**, Potomac, MD (US) delete "**Joel N. Kline**, Iowa City, IA (US)"
Item [57], **ABSTRACT**,
Line 5, after the word "useful" insert -- as --.

Column 3,
Line 5, delete "(dG),(dC)" and insert -- (dG)-(dC) --,
Line 5, delete "(dG,dC)" and insert -- (dG·dC) --,
Line 10, delete "dG,dC" and insert -- dG·dC --,
Line 11, after the word "Tokunaga," insert -- T., --,
Line 12, delete "α/b" and insert -- α/β --,
Line 13, delete "—g" and insert -- γ --,
Line 32, delete "0.1" and insert -- O. --,
Line 39, delete "Ig2b" and insert -- Ig2b --
Line 40, delete "g2b" and insert -- γ2b --

Column 4,
Line 18, after "H." insert --, --.
Line 26, after "1" insert -- β --,
Line 32, delete "B" and insert -- β --,
Line 36, delete "TGF-B1" and insert -- TGF-β1 --,
Line 39, delete "DRa" and insert -- DRα --,

Column 5,
Line 26, after the word "functions" delete ";",
Lines 41, 43, 45, 47 and 49, delete "E1A" and insert -- E1a --

Column 6,
Line 34, after the word "that" delete "that".

Column 8,
Line 3, delete "5’CCATGACGTTCTGATGCT3’" and insert -- 5’TCCATGACGTTCTGATGCT3’ --,

Column 9,
Line 40, delete "IFN-g" and insert -- IFN-γ --,
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**Column 11.**
Line 30, delete “immunostimulatory” and insert -- immunostimulatory --.
Line 34, delete “5’N2X1CGX2N3’” and insert -- 5’N1X1CGX2N3’ --.
Line 52, after the word “that” delete “that”.
Line 57, delete “invnetion” and insert -- invention --.
Line 67, after the word “a” delete “a”.

**Column 12.**
Line 31, delete “TCGTCGTTTTGTCGGTTTGTGCTGT” and insert -- TCGTCGTTTTGTCGGTTTGTGCTGT --.
Line 37, delete “TCGTCGTTTTGTCGGTTTGTGCTGT” and insert -- TCGTCGTTTTGTCGGTTTGTGCTGT --.

**Column 13.**
Line 53, delete “ABCDEED’C’B’A’” and insert -- ABCDEE’D’C’B’A’ --.

**Column 16.**
Line 19, delete “id” and insert -- Id --.
Lines 37 and 39, after the word “ends” delete “.”.
Table 1, delete “Oligonucleotide” and insert -- Oligonucleotide --.

**Column 17.**
Table 1, delete “Oligonucleotide” and insert -- Oligonucleotide --.
Table 1, after the No. “3Da”(SEQ ID NO:21), delete “………C……….” and insert -- ………..C……….. --.

**Column 20.**
Line 35, delete “:.” and insert -- “ --.

**Column 21.**
Line 23, delete “nonresponseive” and insert -- nonresponsive --.

**Column 22.**
Line 24, delete “harbor” and insert -- Harbor --.
Line 45, delete “lipopolysaccharide” and insert -- lipopolysaccharide --.
Line 59, after the word “activating” delete “;”.

**Column 24.**
Line 17, delete “moths” and insert -- motifs --.
Table 5, delete “secretion” and insert -- secretion --.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**Column 25.**
Table 5, delete “secretion” and insert -- secretion --.
Table 5, delete “i” and insert -- 1 --.
Line 39, after the word “residues” insert -- 6-11 --.
Line 50, delete “8” and insert -- 88 --.

**Column 26.**
Line 54, after the word “human” delete “,.”.

**Column 27.**
Line 15, after the word “IL-” insert -- 6 --.
Line 16, delete “6promoter” and insert -- promoter --.

**Column 28.**
Line 56, delete “All” and insert -- all --.

**Column 30.**
Line 27, after the word “NK” delete “;”.
Line 29, delete “α/b” and insert -- α/β --.
Table 9, after the number “1629” delete “------gtc------(SEQ ID NO:50)” and insert
-- ------gtc------(SEQ ID NO:41) --.
Table 9, after the number “1765” delete “------Z------(SEQ ID NO:53)” and insert
-- ------Z------(SEQ ID NO:44) --.

**Column 31.**
Line 2, after the word “immune” delete “,”.

**Column 33.**
Table 11, delete “Phosphorothioate” and insert -- Phosphorothioate --.
Table 11, after the number “1982” delete “TCCAGGACTTCTCTCAAGTT” and insert
-- TCCAGGACTTCTCTCAAGTT --.

**Columns 33-34.**
Table 12, in the heading, delete “Index 11” and insert -- Index1 --.

**Columns 35-36.**
Table 12, in the heading, delete “Index 11” and insert -- Index1 --.

**Column 35.**
Line 65, delete “IL2” and insert -- IL 12 --.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**Column 37.**
Line 54, after the word “Immunostimulatory” delete “,”.
Line 60, delete “2nd” and insert -- and --.

**Column 39.**
Line 8, delete “sis” and insert -- as --.

**Column 41.**
Line 24, delete “oiler” and insert -- other --.

**Columns 41-42.**
Table 15, in the line beginning with “TABLE 15”, delete “3774” and insert -- J774 --.
Table 15, after the word “(TNF-α” insert -- ) --.

**Column 43.**
Line 55, delete “*Comparable amounts*” and insert -- Comparable amounts --.
Line 56, delete “*ribosomal μDNA*” and insert -- ribosomal mDNA --.
Line 57, delete “*tides*” and insert -- times --.

**Column 46.**
Line 19, after the word “acids” delete “,”.
Line 47, delete “unethylated” and insert -- unmethylated --.
Line 48, delete “TCCATGACGTTCCTGACGT” and insert
-- TCCATGACGTTCCTGACGT --.
Line 63, delete “*parenteral*” and insert -- parenteral --.

**Column 48.**
Line 39, delete “37 C” and insert -- 37° C. --.
Line 40, delete “al5so” and insert -- also --.
Line 58, after the word “washed” delete “,”.
Line 65, after the word “*centrifuged*” delete “,”.

**Column 49.**
Line 9, delete “phosphorothioate” and insert -- phosphorothioate --.
Line 31, after the number “37” insert -- ° --.
Line 51, delete “*Elisa*” and insert -- ELISA --.

**Column 50.**
Line 4, delete “Homby” and insert -- Hornby --.
Line 62, delete “NaHC3” and insert -- NaHCO3 --.
Line 64, after the number “6.6 mM” delete “,”.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**Column 51.**
Line 26, delete “Dalhman” and insert -- Dallman --.
Line 39, delete “(tired)” and insert -- dried --.
Line 56, delete “electroporated” and insert -- electroporated --.

**Column 52.**
Line 22, delete “benzoynhcaptoethyl” and insert -- benzoylmercaptoethyl --.
Line 39, after the word “kinetics” delete “,”.

**Column 53.**
Line 1, delete “(5’ GAGAACCTGGACCTTCCAT)” and insert
-- (5’ GAGAACGTGGACCTTCCAT) --.
Line 3, delete “(5’ TCCATGTCGTCCTGTAGCTGCT)” and insert
-- (5’ TCCATGTCGTCCTGTAGCTGCT) --.
Line 5, delete “(5’ GGCGTTATCTGACTCGCC)” and insert
-- (5’ GGCGTTATCTGACTCGCC) --.
Line 7, delete “(5’ CCTACGTGTTATGCTCCGTTCCAGCT)” and insert
-- (5’ CCTACGTGTTATGCTCCGTTCCAGCT) --.
Line 52, before the word “PBMO” insert -- ( --.

**Column 54.**
Lines 26-27, delete “TCCATGACGGTCTGACGT” and insert
-- TCCATGACGGTCTGACGT --.

**Column 55.**
Line 1, delete “IL-12” and insert -- IL-12 --.

**Column 99.**
Line 38, delete “5’X1X2CGX3X3” and insert -- 5’X1X2CGX3X3’ --.
Line 54, delete “GpT, GpA,” and insert -- CpT, CpA, --.

**Column 100.**
Line 53, delete “5’X1X2CGX3X3” and insert -- 5’X1X2CGX3X3’ --.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 101,
Line 14, delete “15” and insert -- 14 --.
Line 57, delete “phosphates” and insert -- phosphate --.
Line 19, delete “5’X_2CGX_3’” and insert -- 5’X_2CGX_3’ --.

Signed and Sealed this
Tenth Day of June, 2003

JAMES E. ROGAN
Director of the United States Patent and Trademark Office
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page should read as follows:

(63) Continuation-in-part of application No. 08/738,652, filed on Oct. 30, 1996, which is a continuation-in-part of application No. 08/386,063, filed February 7, 1995, which is a continuation-in-part of application No. 08/276,358, filed July 15, 1994.

Title Page, item [63] please amend the Related Applications section in col. 1, line 4 should read as follows:

RELATED APPLICATIONS

This application is a continuation-in-part of application No. 08/738,652, filed on Oct. 30, 1996, which is a continuation-in-part of application No. 08/386,063, filed February 7, 1995, which is a continuation-in-part of application No. 08/276,358, filed July 15, 1994.

Signed and Sealed this
Thirtieth Day of March, 2010

[Signature]

David J. Kappos
Director of the United States Patent and Trademark Office